Minnesota
|
|
3841
|
|
41-1458152
|
(State
of Incorporation)
|
|
(Primary
Standard Industrial Classification Code Number)
|
|
(IRS
Employer ID No.)
|
Title
Of Each Class Of Securities To Be Registered
|
Amount
To Be Registered (1)
|
Proposed
Maximum Offering Price Per Unit
|
Proposed
Maximum Aggregate Offering Price
|
Amount
Of Registration Fee
|
|||||||||
|
|
|
|
|
|||||||||
Common
stock, $0.001 par value, issuable upon conversion of preferred
stock
|
43,219
|
$
|
5.38(2
|
)
|
$
|
232,518
|
$
|
24.88(3
|
)
|
||||
Common
stock, $0.001 par value, issuable upon exercise of stock
options
|
218,454
|
$
|
5.38(2
|
)
|
$
|
1,175,283
|
$
|
125.76(3
|
)
|
||||
Common
stock, $0.001 par value
|
4,004,264
|
$
|
5.45(4
|
)
|
$
|
21,823,238
|
$
|
2334.87(3
|
)
|
||||
Common
stock, $0.001 par value, issuable upon exercise of
warrants
|
371,163
|
$
|
5.38(2
|
)
|
$
|
1,996,857
|
$
|
213.66(3
|
)
|
||||
|
|||||||||||||
Total
|
4,637,100
|
$
|
25,227,896
|
$
|
2699.17(3
|
)
|
(1)
|
Includes
shares of our common stock, par value $0.001 per share, which
may be
offered pursuant to this registration statement, a portion of
which shares
are issuable upon conversion of preferred stock and convertible
debentures
and exercise of warrants and stock options held by the selling
shareholders. In addition to the shares set forth in the table,
the amount
to be registered includes an indeterminate number of shares,
including
those issuable upon conversion of the preferred stock and convertible
debentures and exercise of the warrants and stock options, as
such number
may be adjusted as a result of stock splits, stock dividends
and similar
transactions in accordance with Rule 416.
|
(2)
|
Estimated
solely for the purpose of calculating the amount of the registration
fee
pursuant to Rule 457(c) under the Securities Act of 1933, as
amended,
based upon the average of the bid and asked prices of the Registrant's
common stock on November 7, 2005.
|
(3)
|
Previously
paid.
|
(4)
|
Represents
a combination of (2) and (5).
|
(5)
|
Estimated
solely for the purpose of calculating the amount of the registration
fee
pursuant to Rule 457(c) under the Securities Act of 1933, as
amended,
based upon the average of the bid and asked prices of the Registrant's
common stock on March 20, 2006.
|
PROSPECTUS
SUMMARY
|
1
|
RISK
FACTORS
|
4
|
USE
OF PROCEEDS
|
13
|
MANAGEMENT'S
DISCUSSION AND ANALYSIS
|
13
|
MARKET
FOR COMMON STOCK
|
18
|
DESCRIPTION
OF BUSINESS
|
19
|
DESCRIPTION
OF PROPERTY
|
39
|
LEGAL
PROCEEDINGS
|
40
|
DIRECTORS,
EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
|
40
|
INDEMNIFICATION
OF DIRECTORS AND OFFICERS
|
46
|
SECURITIES
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
46
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
|
48
|
SELLING
SHAREHOLDERS
|
50
|
PLAN
OF DISTRIBUTION
|
62
|
DESCRIPTION
OF SECURITIES
|
63
|
LEGAL
MATTERS
|
65
|
EXPERTS
|
65
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS
|
65
|
FURTHER
INFORMATION
|
66
|
Common
Stock Offered
|
|
4,637,100
shares by selling shareholders
|
Offering
Price
|
Market
price or negotiated price
|
|
Common
Stock Outstanding Before the Offering
|
14,717,686
shares as of April 25, 2006
|
|
Use
of Proceeds
|
|
We
will not receive any proceeds from the resale of the shares offered
hereby, all of which proceeds will be paid to the selling
shareholders.
|
Risk
Factors
|
|
The
purchase of our common stock involves a high degree of risk. You
should
carefully review and consider the "RISK FACTORS" section beginning
on page
4.
|
OTC
Bulletin Board Symbol
|
|
ISRY.OB
|
·
|
our
achievement of product development objectives and milestones;
|
·
|
demand
and pricing for the Company's products;
|
·
|
effects
of aggressive competitors;
|
·
|
hospital,
clinic and physician buying decisions;
|
·
|
research
and development and manufacturing expenses;
|
·
|
patient
outcomes from our therapy;
|
·
|
physician
acceptance of our products;
|
·
|
government
or private healthcare reimbursement policies;
|
·
|
our
manufacturing performance and capacity;
|
·
|
incidents,
if any, that could cause temporary shutdown of our manufacturing
facilities;
|
·
|
the
amount and timing of sales orders;
|
·
|
rate
and success of future product approvals;
|
·
|
timing
of FDA approval, if any, of competitive products and the rate of
market
penetration of competing products;
|
·
|
seasonality
of purchasing behavior in our market;
|
·
|
overall
economic conditions; and
|
·
|
the
successful introduction or market penetration of alternative therapies.
|
Period
|
High
|
Low
|
|||||
October
1, 2003 - December 31, 2004
|
N/A
|
N/A
|
|||||
January
2, 2005 - March 31, 2005
|
*
|
*
|
|||||
April
1, 2005 - June 30, 2005(1)
|
N/A
|
N/A
|
|||||
July
1, 2005 - September 30, 2005
|
$
|
5.95
|
$
|
1.00
|
|||
October
1, 2005 - December 31, 2005
|
$
|
8.25
|
$
|
4.50
|
*
|
Less
than $0.01.
|
(1)
|
Due
to our change of fiscal year end from September 30 to June 30, our
2005
fiscal year was only nine months
long.
|
Plan
Category
|
Number
of securities to be issued upon exercise of outstanding options,
warrants
and rights (#)
|
Weighted-average
exercise price of outstanding options, warrants and rights
($)
|
Number
of securities remaining available for future issuance under equity
compensation plans
|
|||||||
Equity
compensation plans approved by shareholders
|
N/A
|
N/A
|
N/A
|
|||||||
Equity
compensation plans not approved by shareholders
|
2,841,716
|
$
|
1.65
|
870,000
|
||||||
Total
|
2,841,716
|
$
|
1.65
|
870,000
|
·
|
Began
offering seeds loaded in sterile strands and needles from IsoRay’s custom
preloading service (March 2006);
|
·
|
Began
radioactive operations in our new manufacturing facility in Richland,
Washington (November 2005);
|
·
|
Deployed
a direct sales force to the market (July 2004 - July
2005);
|
·
|
Developed
a treatment protocol for prostate cancer with a leading oncologist
(January 2005);
|
·
|
Treated
the first patient (October 2004);
|
·
|
Commenced
production of the 131Cs
seed (August 2004);
|
·
|
Filed
five additional patent applications for 131Cs
and 90Y
processes (November 2003 -August 2004);
|
·
|
Obtained
a Nuclear Regulatory Commission Sealed Source and Device Registration
required by the Washington State Department of Health and the FDA
(September 2004);
|
·
|
Received
a Radioactive Materials License from the Washington State Department
of
Health (July 2004);
|
·
|
Implemented
an ISO-9000 Quality Management System and production operating procedures
(under continuing development);
|
·
|
Signed
a Commercial Work for Others Agreement between Battelle (manager
of the
Pacific Northwest National Laboratory or PNNL) and IsoRay Medical,
allowing initial production of seeds through 2006 at PNNL (April
2004);
|
·
|
Raised
over $17.5 M in debt and equity funding (September 2003 - February
2006)
|
·
|
Obtained
favorable Medicare reimbursement codes for the Cs-131 brachytherapy
seed
(November 2003);
|
·
|
Obtained
FDA 510(k) approval to market the first product: the 131Cs
brachytherapy seed (March 2003);
|
·
|
Completed
initial radioactive seed production, design verification, computer
modeling of the radiation profile, and actual dosimetric data compiled
by
the National Institute of Standards and Technology and PNNL (October
2002); and
|
·
|
Obtained
initial patent for 131Cs
isotope separation and purification (May 2000).
|
Stages
|
Characteristics
of prostate cancer
|
|
T1
or T2
|
Localized
in the prostate
|
|
T3
or T4
|
Locally
advanced
|
|
N+
or M+
|
Spread
to pelvic lymph nodes (N+)or distant organs
(M+)
|
·
|
A
twelve-year clinical study published in the 2004 Supplement of the
International
Journal of Radiation Oncology, Biology and Physics,
reported that the relative survival rate is 84% for low risk cancer
patients, 78% for intermediate risk cancer patients and 68% for high
risk
cancer patients. The study was conducted by Dr. Lou Potters, et al.
of the
New York Prostate Institute and included 1,504 patients treated with
brachytherapy between 1992 and 2000.
|
·
|
A
study published in the January 2004 issue of the International
Journal of Radiation Oncology, Biology and Physics,
reported that brachytherapy, radical prostatectomy, high-dose external
beam radiation therapy and combined therapies produced similar cure
rates.
The study was conducted by Dr. Patrick Kupelian, Dr. Louis Potters,
et al.
and included 2,991 patients with Stage T1 or T2 prostate cancer.
Of these
patients, 35% of patients underwent surgery, 16% received low-dose
EBRT,
10% received high-dose EBRT, 7% received combination therapy and
32%
received brachytherapy. After five years, the biochemical relapse-free
survival rate was 83% for brachytherapy, 81% for radical prostatectomy,
81% for high-dose EBRT, 77% for combination therapy and 51% for low-dose
EBRT.
|
·
|
A
nine-year clinical study published in the March 2000 issue of the
International
Journal of Radiation Oncology, Biology and Physics,
reported that 83.5% of patients treated with the Pd-103 device were
cancer-free at nine years. The study was conducted by Dr. John Blasko
of
the Seattle Prostate Institute and included 230 patients with clinical
stage T1 and T2 prostate cancer. Only 3% experienced cancer recurrence
in
the prostate.
|
·
|
Results
from a 10-year study conducted by Dr. Datolli and Dr. Wallner published
in
the International
Journal of Radiation Oncology, Biology and Physics
in
September 2002, were presented at the October 2002 American Society
for
Therapeutic Radiology and Oncology conference confirming the effectiveness
of the Pd-103 seed in patients with aggressive cancer who previously
were
considered poor candidates for brachytherapy. The 10-year study was
comprised of 175 patients with Stage T2-T3 prostate cancer treated
from
1991 through 1995. Of these patients, 79 percent remained completely
free
of cancer without the use of hormonal therapy or chemotherapy.
|
·
|
A
study by the Northwest Prostate Institute in Seattle, Washington
reported
79% disease-free survival at 12 years for brachytherapy in combination
with external beam radiation (Ragde, et
al.,
Cancer,
July 2000). The chance of cure from brachytherapy is nearly 50% higher
than for other therapies for men with large cancers (PSA 10-20) and
over
twice as high as other therapies for men with the largest cancers
(PSA
20+) (K. Wallner, Prostate
Cancer: A Non-Surgical Perspective,
Smart Medicine Press, 2000).
|
·
|
Continue
to introduce the IsoRay 131Cs
seed into the U.S. brachytherapy market.
Utilizing a direct sales organization and selected channel partners,
IsoRay Medical intends to capture a leadership position by expanding
overall use of the brachytherapy procedure for prostate cancer, capturing
much of the incremental market growth and taking market share from
existing competitors.
|
·
|
Create
a state-of-the-art manufacturing process.
IsoRay Medical has constructed a state-of-the-art manufacturing facility
in Richland, Washington in its newly leased facility, to implement
our
proprietary manufacturing process which is designed to improve profit
margins and provide adequate manufacturing capacity to support future
growth and ensure quality control. If Initiative 297 presents a strategic
roadblock to the Company, IsoRay plans to construct a permanent
manufacturing facility in another state. Working with leading scientists,
IsoRay Medical intends to design and create a proprietary separation
process to manufacture enriched barium, a key source material for
131Cs,
to ensure adequate supply and greater manufacturing efficiencies.
Also
planned is a custom preloading service to supply pre-loaded needles,
stranded seeds and pre-loaded cartridges used in the implant procedure.
IsoRay Medical plans to enter into a long-term program with a leading
brachytherapy seed automation design and engineering company to design
and
build a highly automated manufacturing process to help ensure consistent
quality and improve profitability.
|
·
|
Introduce
Cesium-131 therapies for other solid cancer tumors.
IsoRay Medical intends to partner with other companies to develop
the
appropriate delivery technology and therapeutic delivery systems
for
treatment of other solid cancer tumors such as breast, lung, liver,
pancreas, neck, and brain cancer. IsoRay Medical's management believes
that the first major opportunities may be for the use of Cesium-131
in
adjunct therapy for the treatment of residual lung and breast cancers.
|
·
|
Introduce
other isotope products to the U.S. market.
IsoRay Medical plans to introduce its Yttrium-90 radioisotope in
2006.
Currently, FDA approved 90Y
manufactured by other suppliers is used in the treatment of non-Hodgkin's
lymphoma and is in clinical trials for other applications. Other
products
may be added in the future as they are developed. IsoRay Medical
has the
ability to make several different isotopes for multiple medical and
industrial applications. During 2005 the Company has identified and
prioritized additional market opportunities for these
isotopes.
|
·
|
Support
clinical research and sustained product development.
The Company plans to structure and support clinical studies on the
therapeutic benefits of Cs-131 for the treatment of solid tumors
and other
patient benefits. We are and will continue to support clinical studies
with several leading radiation oncologists to clinically document
patient
outcomes, provide support for our product claims and compare the
performance of our seeds to competing seeds. IsoRay Medical plans
to
sustain long-term growth by implementing research and development
programs
with leading medical institutions in the U.S. to identify and develop
other applications for IsoRay Medical's core radioisotope technology.
|
Cesium-131
|
Palladium-103
|
Iodine-125
|
|
Half
Life
|
9.7
Days
|
17.5
days
|
60
days
|
Energy
|
29
KeV+
|
22
KeV+
|
28
KeV+
|
Dose
Delivery
|
90%
in 33 days
|
90%
in 58 days
|
90%
in 204 days
|
Total
Dose
|
100
Gy
|
125
Gy
|
145
Gy
|
Anisotropy
Factor*
|
.969
|
.877
(TheraSeed® 2000)
|
.930
(OncoSeed® 6711)
|
+KeV
= kiloelectron volt, a standard unit of measurement for electrical
energy.
*Degree
of symmetry of therapeutic dose, a factor of 1.00 indicates symmetry.
|
·
|
Isotope
Generation. The
radioactive isotope Cs-131 is normally produced by placing a quantity
of
stable non-radioactive barium (ideally pure Ba-130) into the neutron
flux
of a nuclear reactor. The irradiation process converts a small
fraction of
this material into a radioactive form of barium (Ba-131). The Ba-131
decays by electron capture to the radioactive isotope of interest
(Cs-131). IsoRay Medical has evaluated several international nuclear
reactors and a few potential facilities in the United States. Due
to the
short half-life of both the Ba-131 and Cs-131 isotopes, these facilities
must be capable of removing irradiated materials from the reactor
core on
a routine basis. Reactor personnel will ship the irradiated barium
on a
pre-determined schedule to our facilities for subsequent separation,
purification and seed assembly. The Company has identified more
than five
reactors in the U.S., Europe and the former Soviet Union that are
capable
of meeting these requirements. This routine isotope generation
cycle at
supplier reactors will allow significant quantities of Ba-131 to
be on
hand at our facilities for the completion of the rest of the manufacturing
process. To ensure reliability of supply, we intend to seek agreements
with multiple facilities to produce Ba-131. As of the date of this
Prospectus, IsoRay Medical has agreements in place with two suppliers
of
irradiated Ba-131. The Company’s agreement with Russia’s Institute of
Nuclear Materials for irradiated Ba-131 has a seven year term (ending
August 25, 2012) and allows the Company to purchase irradiated
Ba-131 for
$300.00 per Curie of the isotope. In addition, the Company is engaged
in
the development of a barium enrichment device that, if successful,
should
reduce the cost of producing Cs-131 while maintaining the purity
and
consistency required in the end product.
|
·
|
Isotope
Separation and Purification. Upon
irradiation of the barium feedstock, the Ba-131 begins decaying
to Cs-131.
At pre-determined intervals the Cs-131 produced is separated from
the
barium feedstock and purified using a proprietary radiochemical
separations process (patent applied for). Due to the high-energy
decay of
Ba-131, this process is performed under stringent radiological
controls in
a highly shielded isolator or "hot cell" using remote manipulators.
After
separating Cs-131 from the energetic Ba-131, subsequent seed processing
may be performed in locally shielded fume hoods or glove boxes.
If
enriched barium feedstock is used, the residual barium remaining
after
subsequent Cs-131 separation cycles ("milkings") will be recycled
back to
the reactor facility for re-irradiation. This material will be
recycled as
many times as economically feasible, which should make the process
more
cost effective. As an alternative to performing the Cs-131 separation
in
our own facilities, IsoRay may enter into agreements with other
entities
to supply "raw" Cs-131 by performing the initial barium/cesium
separation
at their facilities, followed by final purification at IsoRay's
facility.
|
·
|
Internal
Seed Core Technology. The
purified Cs-131 isotope will be incorporated into an internal assembly
that contains a binder, spacer and X-ray marker. This internal
core
assembly is subsequently inserted into a titanium case. The dimensional
tolerance for each material is extremely important. Several carrier
materials and placement methods have been evaluated, and through
a process
of elimination, we have developed favored materials and methods
during our
laboratory testing. The equipment necessary to produce the internal
core
includes accurate cutting and gauging devices, isotope incorporation
vessels, reaction condition stabilization and monitoring systems,
and
tools for placing the core into the titanium tubing prior to seed
welding.
|
·
|
Seed
Welding. Following
production of the internal core and placement into the titanium
capsule, a
seed is hermetically sealed to produce a sealed radioactive source
and
biocompatible medical device. This manufacturing technology requires:
accurate placement of seed components with respect to the welding
head,
accurate control of welding parameters to ensure uniform temperature
and
depth control of the weld, quality control assessment of the weld
integrity, and removal of the finished product for downstream processing
or rejection of unacceptable materials to waste. Inspection systems
are
capable of identifying and classifying these variations for quality
control ensuring less material is wasted. Finally, the rapid placement
and
removal of components from the welding zone will affect overall
product
throughput.
|
·
|
Quality
Control. We
have established procedures and controls to meet all FDA and ISO
9001:2000
Quality Standards. Product quality and reliability will be secured
by
utilizing multiple sources of irradiation services, feedstock material,
and other seed manufacturing components. An intensive production
line
preventive maintenance and spare parts program will be implemented.
Also,
an ongoing training program will be established for customer service
to
ensure that all regulatory requirements for the FDA, DOT and applicable
nuclear radiation and health authorities are fulfilled.
|
·
|
Loose
seeds
|
·
|
Pre-loaded
needles
(loaded with 3 to 5 seeds and spacers)
|
·
|
Strands
of seeds
(consists of seeds and spacers in a biocompatible "shrink wrap")
|
·
|
Pre-loaded
Mick cartridges
(fits the Mick applicator - seed manufacturers usually load and sterilize
Mick cartridges in their own manufacturing
facilities)
|
Chicago
Prostate Cancer Center
|
Westmont,
IL
|
Community
Hospital of Los Gatos
|
Los
Gatos, CA
|
Name
|
Age
|
Position
|
Roger
E. Girard
|
62
|
CEO,
President, Chairman
|
Michael
K. Dunlop
|
54
|
CFO,
Treasurer
|
David
J. Swanberg
|
49
|
Exec.
VP-Operations, Secretary, Director
|
Robert
R. Kauffman
|
65
|
Director
|
Thomas
C. Lavoy
|
46
|
Director
|
Stephen
R. Boatwright
|
42
|
Director
|
Dwight
Babcock
|
58
|
Director
|
Albert
Smith
|
62
|
Director
|
Name
|
Age
|
Position
with IsoRay Medical, Inc.
|
Lane
Bray
|
77
|
Chief
Chemist
|
Garrett
Brown
|
43
|
Chief
Technology Officer
|
Oleg
Egorov
|
36
|
Director
of Radiochemical Development
|
Lisa
Mayfield
|
37
|
Director
of Operations
|
Keith
Welsch
|
59
|
Chief
Quality Officer
|
|
Annual
Compensation
|
Long-Term
Compensation Awards
|
||||||||||||||
Name
and Principal Position
|
Fiscal
Year(1)
|
Salary
|
Restricted
Stock Awards
|
Securities
Underlying Options
|
All
Other Compensation
|
|||||||||||
Roger
Girard, Chief Executive Officer(2)
|
2005
|
$
|
113,958
|
--
|
--
|
--
|
||||||||||
2004
|
$
|
71,031
|
$
|
9,900
|
513,840
|
--
|
||||||||||
2003
|
$
|
4,000
|
$
|
49,900
|
--
|
--
|
||||||||||
Thomas
Scallen, Former Chief Executive Officer(3)
|
2005
|
--
|
--
|
--
|
$
|
50,000(4
|
)
|
|||||||||
2004
|
--
|
$
|
7,871
|
--
|
--
|
|||||||||||
2003
|
--
|
--
|
--
|
--
|
Number
of Securities Underlying Unexercised Options at Fiscal
Year-End(#)
|
Value
of Unexercised In-the-Money Options at Fiscal Year-End($)
|
||||||||||||||||||
Name
|
Number
of Shares Acquired on Exercise (#)
|
Value
Realized ($)
|
Exercisable
|
Unexercisable
|
Exercisable
|
Unexercisable
|
|||||||||||||
Roger
Girard(1)
|
0
|
0
|
0
|
0
|
n/a
|
n/a
|
|||||||||||||
Thomas
Scallen
|
0
|
0
|
0
|
0
|
n/a
|
n/a
|
COMMON
STOCK SHARE OWNERSHIP AS OFAPRIL 25, 2006
|
|||||||||||||
Name
and Address of Beneficial Owner(1)
|
Amount
of Common Shares Owned
|
Derivative
Securities Exercisable or Convertible Within 60 Days of April 25,
2006
|
Total
Common Shares Beneficially Owned
|
Percent
of Common Shares Owned(2)
|
|||||||||
Roger
Girard, Chief Executive
Officer,
President and
Chairman
|
338,460
|
513,841
|
852,301
|
5.60
|
%
|
||||||||
Michael
Dunlop, Chief
Financial
Officer
|
136,618
|
150,000
|
286,618
|
1.93
|
%
|
||||||||
David
Swanberg, Exec. Vice
President
and Director
|
314,327
|
165,500
|
479,827
|
3.22
|
%
|
||||||||
Robert
Kauffman, Director
|
43,801
|
100,000
|
143,801
|
0.97
|
%
|
||||||||
Thomas
Lavoy, Director
|
8,426
|
100,000
|
108,426
|
0.73
|
%
|
||||||||
Stephen
Boatwright, Director
|
0
|
184,236
|
184,236
|
1.24
|
%
|
||||||||
Albert
Smith, Director
|
108,947
|
50,000
|
158,947
|
1.08
|
%
|
||||||||
Dwight
Babcock, Director
|
42,402
|
50,000
|
92,402
|
0.63
|
%
|
||||||||
Thomas
Scallen, Former Chief
Executive
Officer(4)
|
329,942
|
0
|
329,942
|
2.24
|
%
|
||||||||
Lawrence
Family Trust(5)
|
888,529
|
0
|
888,529
|
6.04
|
%
|
||||||||
Anthony
Silverman(6)
|
624,699
|
321,391
|
946,090
|
6.29
|
%
|
||||||||
All
Officers and Directors
|
|||||||||||||
as
a group (8 persons)
|
1,002,277
|
1,589,364
|
2,591,641
|
15.89
|
%
|
(1)
|
Except
as otherwise noted, the address for each of these individuals is
c/o
IsoRay, Inc., 350 Hills St., Suite 106, Richland, WA
99354.
|
(2)
|
Percentage
ownership is based on 14,717,686 shares of Common Stock outstanding
on
April 25, 2006. Shares of Common Stock subject to stock options,
warrants
or convertible debentures which are currently exercisable/convertible
or
will become exercisable/convertible within 60 days after April
25, 2006
are deemed outstanding for computing the percentage ownership of
the
person or group holding such options, but are not deemed outstanding
for
computing the percentage ownership of any other person or group.
|
(3)
|
Mr.
Scallen's address is 4701 IDS Center, Minneapolis, MN 55402.
|
(4)
|
The
address of the Lawrence Family Trust is 285 Dondero Way, San Jose,
CA
95119.
|
(5)
|
Mr.
Silverman’s address is 2747 Paradise Road, #903, Las Vegas, NY 98109.
64,876 of the shares of common stock and 37,500 of the derivative
securities beneficially owned by Mr. Silverman are held of record
by
Katsinam Partners, LP, an entity of which Mr. Silverman is a member
of the
general partner.
|
|
Name
|
Beneficial
Ownership Before the Offering (1)
|
Percentage
of Common Stock Owned Before Offering
|
Shares
of Common Stock Included in Prospectus (2)
|
Shares
of Common Stock Issuable Upon Conversion or Exercise of Preferred
Stock,
Options or Warrants Included in Prospectus (3)
|
Exercise
Price of Option or Warrant Included in Prospectus
|
Grant
Date of Option or Warrant Included in Prospectus
|
Term
of Option or Warrant Included in Prospectus
|
Total
Shares of Common Stock Included in Prospectus
|
Ownership
Footnote
|
Beneficial
ownership After the Offering
(4)
|
Percentage
of Common Stock Owned After Offering
(4)
|
|||||||||||||||||||||||
Agger
Capital
|
3,832
|
*
|
3,832
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
3,832
|
6
|
0
|
*
|
||||||||||||||||||||||||
Alan
E. Waltar and Anna E. Waltar, Trustees of the Alan E. and Anna
E. Waltar
Trust U/A DTD 7/3/98
|
57,982
|
*
|
7,480
|
-
|
7,480
|
1
|
50,502
|
*
|
||||||||||||||||||||||||||
All
Seasons Painting Co. (Richard Rusch)
|
21,327
|
*
|
4,265
|
-
|
4,265
|
2
|
17,062
|
*
|
||||||||||||||||||||||||||
Anastassatos, Efthimios Christopher | 14,819 |
*
|
4,819
|
-
|
4,819
|
4
|
10,000
|
*
|
||||||||||||||||||||||||||
Babcock,
Dwight W.
|
102,207
|
*
|
22,962
|
-
|
22,962
|
3,8
|
79,245
|
*
|
||||||||||||||||||||||||||
Babcock,
Elaine
|
2,695
|
*
|
539
|
-
|
539
|
8
|
2,156
|
*
|
||||||||||||||||||||||||||
Bales,
Matt
|
5,178
|
*
|
1,036
|
-
|
1,036
|
7
|
4,142
|
*
|
||||||||||||||||||||||||||
Bartholomew,
Richard & Suzanne
|
17,772
|
*
|
3,554
|
-
|
3,554
|
2
|
14,218
|
*
|
||||||||||||||||||||||||||
Bates,
Christopher Matthew
|
4,265
|
*
|
853
|
-
|
853
|
2
|
3,412
|
*
|
||||||||||||||||||||||||||
Bates,
Robert and Lisa
|
47,873
|
*
|
16,335
|
-
|
16,335
|
1,2,3
|
31,538
|
*
|
||||||||||||||||||||||||||
Bavispe
Limited Partnership (Robert Caylor)
|
126,283
|
*
|
14,235
|
-
|
14,235
|
3
|
112,048
|
1.28
|
%
|
|||||||||||||||||||||||||
Bear
Stearns Securities Corporation Custodian Michael Eric Jacobson
IRA(10)
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Bear
Stearns Securities Corporation Custodian Mishawn Marie Nelson
IRA
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Bear
Stearns Securities Corporation Custodian Steven Mark Nelson
IRA(10)
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Berglin,
Bruce D. and Doneda E.
|
15,475
|
*
|
5,475
|
-
|
5,475
|
3
|
10,000
|
*
|
||||||||||||||||||||||||||
Berglund,
Greg
|
35,769
|
*
|
15,769
|
-
|
15,769
|
3,4
|
20,000
|
*
|
||||||||||||||||||||||||||
Betty
McCormick Trust
|
7,108
|
*
|
1,422
|
-
|
1,422.
|
2
|
5,686
|
*
|
||||||||||||||||||||||||||
Bock,
Daniel
|
18,072
|
*
|
18,072
|
-
|
18,072
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Boesel,
John(10)
|
1,084
|
*
|
1,084
|
$
|
0.59
- 2.37
|
3/25/2005
|
3/25/2007
|
1,084
|
6
|
0
|
*
|
|||||||||||||||||||||||
Boggess,
Thomas S. IV and Jonette D. JTROS
|
36,145
|
*
|
36,145
|
-
|
36,145
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Boland,
John C.
|
28,437
|
*
|
5,687
|
-
|
5,687
|
2
|
22,750
|
*
|
||||||||||||||||||||||||||
Boland,
John L.
|
116,098
|
*
|
10,384
|
7,109
|
17,493
|
1,2
|
98,605
|
1.13
|
%
|
|||||||||||||||||||||||||
Bonanza,
LLC (David and Donna Whitehead)
|
39,672
|
*
|
25,454
|
-
|
25,454
|
2,3
|
14,218
|
*
|
||||||||||||||||||||||||||
Boster,
Gary
|
29,399
|
*
|
29,399
|
-
|
29,399
|
5
|
0
|
*
|
||||||||||||||||||||||||||
Bragdon,
George and Barbara
|
2,105
|
*
|
421
|
-
|
421
|
8
|
1,684
|
*
|
||||||||||||||||||||||||||
Brown
Larsen, Pamela
|
14,218
|
*
|
2,844
|
2,844
|
2
|
11,374
|
*
|
|||||||||||||||||||||||||||
Brown,
Alexis and Alan
|
4,211
|
*
|
842
|
-
|
842
|
8
|
3,369
|
*
|
||||||||||||||||||||||||||
Brown,
Anne J.
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Brown,
Garrett N.
(6)
|
552,237
|
4.13
|
%
|
31,546(7
|
)
|
-
|
31,546
|
1
|
520,691
|
5.97
|
%
|
|||||||||||||||||||||||
Bunting,
Brandt E. & Collen M.
|
38,435
|
*
|
5,687
|
-
|
5,687
|
2
|
32,748
|
*
|
||||||||||||||||||||||||||
Burstein,
Fred
|
290,016
|
2.17
|
%
|
290,016
|
-
|
290,016
|
5
|
0
|
*
|
|||||||||||||||||||||||||
Burstein,
Fred IRA
|
16,425
|
*
|
16,425
|
-
|
16,425
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Cangiane,
Lorraine and Gilson, Bernard
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Carroll,
Bridget M.
|
14,218
|
*
|
14,218
|
-
|
14,218
|
2
|
0
|
*
|
||||||||||||||||||||||||||
Chapman,
Milton A
|
48,782
|
*
|
9,756
|
-
|
9,756
|
1
|
39,026
|
*
|
||||||||||||||||||||||||||
Clark,
R. Jeanne
|
25,541
|
*
|
4,878
|
230
|
5,108
|
2
|
20,433
|
*
|
||||||||||||||||||||||||||
Clement,
James H.
|
20,046
|
*
|
7,642
|
747
|
$
|
1.06
|
2/28/2005
|
2/28/2007
|
8,388
|
2,3
|
11,657
|
*
|
||||||||||||||||||||||
Clerf,
Craig
|
1,300
|
*
|
260
|
-
|
260
|
1
|
1,040
|
*
|
||||||||||||||||||||||||||
Clerf,
Robert
|
1,950
|
*
|
390
|
-
|
390
|
1
|
1,560
|
*
|
Clerf,
Roger
|
3,251
|
*
|
650
|
-
|
650
|
1
|
2,601
|
*
|
||||||||||||||||||||||||||
Cohen,
Loren
|
26,426
|
*
|
16,426
|
-
|
16,426
|
3
|
10,000
|
*
|
||||||||||||||||||||||||||
Collier
Living Trust
|
44,885
|
*
|
7,545
|
-
|
7,545
|
2
|
37,340
|
*
|
||||||||||||||||||||||||||
Cone-Gilreath
Law Firm(Douglas Nicholson)
|
48,782
|
*
|
9,756
|
-
|
9,756
|
1
|
39,026
|
*
|
||||||||||||||||||||||||||
Conner
III, Thomas E.
|
33,698
|
*
|
4,740
|
-
|
4,740
|
2
|
28,958
|
*
|
||||||||||||||||||||||||||
Craddock,
Steven Lee
|
7,229
|
*
|
7,228
|
-
|
7,228
|
4
|
1
|
*
|
||||||||||||||||||||||||||
Daniels,
Frederic R. & Anita C. Family Trust
|
72,477
|
*
|
9,597
|
2,488
|
$
|
1.06
|
2/28/2005
|
2/28/2007
|
12,085
|
2
|
60,391
|
*
|
||||||||||||||||||||||
Daswick,
Gregory
|
10,663
|
*
|
2,133
|
-
|
2,133
|
2,3
|
8,530
|
*
|
||||||||||||||||||||||||||
Daswick,
Michael and Kimberly
|
62,943
|
*
|
8,589
|
-
|
8,589
|
2,3
|
54,354
|
*
|
||||||||||||||||||||||||||
DFC
401(k) Profit Sharing Plan FBO Benjamin J. Schwartz
|
24,882
|
*
|
5,564
|
-
|
5,564
|
2
|
19,318
|
*
|
||||||||||||||||||||||||||
Douglas
D. Thornton Family Trust
|
308,957
|
2.31
|
%
|
61,791
|
-
|
61,791
|
1
|
247,166
|
2.83
|
%
|
||||||||||||||||||||||||
Dunlop,
Michael(5)
(6)
|
286,618
|
2.14
|
%
|
24,746(7
|
)
|
-
|
24,746
|
1
|
261,872
|
3.00
|
%
|
|||||||||||||||||||||||
Ecclestone,
Andrew
|
59,842
|
*
|
59,842
|
-
|
59,842
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Edmund,
Robert
|
3,369
|
*
|
674
|
-
|
674
|
8
|
2,695
|
*
|
||||||||||||||||||||||||||
Engels,
Kevin F.
|
18,423
|
*
|
1,685
|
-
|
1,685
|
8
|
16,738
|
*
|
||||||||||||||||||||||||||
Fabri,
Jon
|
43,423
|
*
|
1,685
|
-
|
1,685
|
8
|
41,738
|
*
|
||||||||||||||||||||||||||
Falls
Rd LLC (Paul Hatch)
|
23,698
|
*
|
4,740
|
-
|
4,740
|
2
|
18,958
|
*
|
||||||||||||||||||||||||||
Feder,
Dr. Henry
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Feidelberg,
Steven O. and Codini, Anna-Maria, Trustees of the Feidelberg-Codini
Family
Trust U/T/A dated April 15, 2003
|
6,024
|
*
|
6,024
|
-
|
6,024
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Fernandez,
Leslie
|
3,688
|
*
|
738
|
738
|
2
|
2,950
|
*
|
|||||||||||||||||||||||||||
Ferrick,
Patrick N.
|
9,479
|
*
|
1,896
|
-
|
1,896
|
2
|
7,583
|
*
|
||||||||||||||||||||||||||
Fookes,
Larry
|
46,529
|
*
|
3,577
|
22,914
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
26,491
|
2,6
|
20,038
|
*
|
||||||||||||||||||||||
Fookes,
Sharon
|
3,553
|
*
|
711
|
-
|
711
|
2
|
2,842
|
*
|
Forest
Ridge Properties, Ltd. (Beverly Unger)
|
12,441
|
*
|
1,244
|
1,244
|
$
|
1.40
|
2/28/2005
|
2/28/2007
|
2,488
|
2
|
9,953
|
*
|
||||||||||||||||||||||
Forsman,
John Arvid
|
14,218
|
*
|
2,844
|
2,844
|
2
|
11,374
|
*
|
|||||||||||||||||||||||||||
Freeman,
Kevin
|
22,440
|
*
|
2,488
|
-
|
2,488
|
2
|
19,952
|
*
|
||||||||||||||||||||||||||
Gainer,
Ronald G. & Linda J.
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Gaines,
Ira J.
|
30,950
|
*
|
10,950
|
-
|
10,950
|
2,3
|
20,000
|
*
|
||||||||||||||||||||||||||
Galanty,
Thomas M.
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Giammattei,
Shawn and Peggy
|
252
|
*
|
50
|
-
|
50
|
8
|
202
|
*
|
||||||||||||||||||||||||||
Girard,
Roger E.
(5) (6)
|
852,301
|
6.38
|
%
|
73,285(7
|
)
|
-
|
73,285
|
1,6
|
779,016
|
8.92
|
%
|
|||||||||||||||||||||||
Gold
Trust Co FBO Don Goeckner IRA
|
86,733
|
*
|
17,346
|
-
|
17,346
|
2
|
69,387
|
*
|
||||||||||||||||||||||||||
Goldsmith,
Hugh G.
|
18,959
|
*
|
3,792
|
3,792
|
2
|
15,167
|
*
|
|||||||||||||||||||||||||||
Goodrich,
Daniel A
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Granger,
Jamie
|
10,529
|
*
|
2,106
|
2,106
|
8
|
8,423
|
*
|
|||||||||||||||||||||||||||
Griffith,
Richard and Barbara
|
17,772
|
*
|
3,554
|
-
|
3,554
|
2
|
14,218
|
*
|
||||||||||||||||||||||||||
Hartley,
James N.
|
9,479
|
*
|
1,896
|
1,896
|
2
|
7,583
|
*
|
|||||||||||||||||||||||||||
Hedstrom,
Gary A.
|
12,527
|
*
|
505
|
-
|
505
|
8
|
12,022
|
*
|
||||||||||||||||||||||||||
Hernandez,
Jesus and Melissa
|
16,955
|
*
|
5,581
|
-
|
5,581
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Holcomb,
Sr,, Hampton A.
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Hostetler
Living Trust
|
18,957
|
*
|
1,896
|
1,896
|
3,791
|
2
|
15,166
|
*
|
||||||||||||||||||||||||||
Huls,
Michael, Roth IRA
|
33,000
|
*
|
33,000
|
-
|
33,000
|
6
|
0
|
*
|
||||||||||||||||||||||||||
Intellegration,
LLP(Christopher Smith)
|
35,526
|
*
|
25,526
|
-
|
25,526
|
6
|
10,000
|
*
|
||||||||||||||||||||||||||
Jackson,
John J. & Ellen K.
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
James
J. Minder & Susan A. Davis Family Trust
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Johnson,
Carolyn M.
|
8,422
|
*
|
1,684
|
-
|
1,684
|
8
|
6,738
|
*
|
||||||||||||||||||||||||||
Johnson,
Tom and Lindsay
|
8,422
|
*
|
1,684
|
-
|
1,684
|
8
|
6,738
|
*
|
Kaiser,
James S.
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Kalos,
Shaun and Cathy
|
2,105
|
*
|
421
|
-
|
421
|
8
|
1,684
|
*
|
||||||||||||||||||||||||||
Kang,
Dr. Young S.
|
16,260
|
*
|
3,252
|
-
|
3,252
|
2
|
13,008
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and John Clark Kaser
|
710
|
*
|
142
|
-
|
142
|
2
|
568
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and John Lucas Kaser
|
1,065
|
*
|
213
|
-
|
213
|
2
|
852
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and Jordan Rae Emmil
|
1,065
|
*
|
213
|
-
|
213
|
2
|
852
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and Kenneth Tyler Emmil
|
1,065
|
*
|
213
|
-
|
213
|
2
|
852
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and Laura Kaser Emmil
|
710
|
*
|
142
|
-
|
142
|
2
|
568
|
*
|
||||||||||||||||||||||||||
Kaser,
Kathryn and Levi Clark Kaser
|
1,065
|
*
|
213
|
-
|
213
|
2
|
852
|
*
|
||||||||||||||||||||||||||
Kauffman,
Robert R.
(5)
|
110,950
|
*
|
10,950
|
-
|
10,950
|
3
|
100,000
|
1.15
|
%
|
|||||||||||||||||||||||||
Kelly,
Gerald
|
4,211
|
*
|
842
|
-
|
842
|
8
|
3,369
|
*
|
||||||||||||||||||||||||||
Kelly,
Richard
|
1,675
|
*
|
1,675
|
$
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
1,675
|
6
|
0
|
*
|
|||||||||||||||||||||||
Kemeny,
Matthias D.
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Kennedy,
Patrick H. & Bonnie M.
(6)
|
54,506
|
*
|
10,941(7
|
)
|
-
|
10,941
|
2
|
43,565
|
*
|
|||||||||||||||||||||||||
Klostermann,
Bill and Donna JTWROS
|
16,425
|
*
|
16,425
|
-
|
16,425
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Kocherer,
Rosalee
|
2,105
|
*
|
421
|
-
|
421
|
8
|
1,684
|
*
|
||||||||||||||||||||||||||
Konietzko,
Neil
|
198,423
|
1.48
|
%
|
1,685
|
-
|
1,685
|
8
|
196,738
|
2.25
|
%
|
||||||||||||||||||||||||
Korb,
Leroy J. MD
|
248,368
|
1.86
|
%
|
45,530
|
20,716
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
66,246
|
1
|
182,122
|
2.09
|
%
|
||||||||||||||||||||
Koslowski,
Barbara
|
8,129
|
*
|
1,626
|
-
|
1,626
|
1
|
6,503
|
*
|
||||||||||||||||||||||||||
Kryszek,
Jakob
|
40,522
|
*
|
8,104
|
-
|
8,104
|
2
|
32,418
|
*
|
||||||||||||||||||||||||||
Lambert,
Pat(10)
|
113,195
|
*
|
33,000
|
14,674
|
$
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
47,674
|
6
|
65,521
|
*
|
||||||||||||||||||||||
Lane
A. & Gwen M. Bray Trust(6)
|
386,997
|
2.90
|
%
|
71,142(7
|
)
|
-
|
71,142
|
1,2
|
315,855
|
3.62
|
%
|
|||||||||||||||||||||||
Lanza,
Costantio IRA Charles Schwab & Co., Inc. Custodian
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Larson,
Damian
|
14,320
|
*
|
2,864
|
-
|
2,864
|
8
|
11,456
|
*
|
||||||||||||||||||||||||||
Lavoy,
Thomas(5)
|
108,423
|
*
|
1,685
|
-
|
1,685
|
8
|
106,738
|
1.22
|
%
|
|||||||||||||||||||||||||
Lawrence
Family Trust(6)
|
888,529
|
6.65
|
%
|
177,706(7
|
)
|
-
|
177,706
|
1
|
710,823
|
8.14
|
%
|
|||||||||||||||||||||||
Lebowitz
Living Trust
|
142,188
|
1.06
|
%
|
28,438
|
-
|
28,438
|
2
|
113,750
|
1.30
|
%
|
||||||||||||||||||||||||
Little,
John W. and Marina Zeiber
|
9,639
|
*
|
6,024
|
-
|
6,024
|
4
|
3,615
|
*
|
||||||||||||||||||||||||||
Livingston,
James P. & Keri Segna
|
24,218
|
*
|
2,844
|
-
|
2,844
|
2
|
21,374
|
*
|
||||||||||||||||||||||||||
Lord,
Brandon
|
421
|
*
|
84
|
-
|
84
|
8
|
337
|
*
|
||||||||||||||||||||||||||
Lord,
Leonard L. and Patricia G.
|
4,211
|
*
|
842
|
-
|
842
|
8
|
3,369
|
*
|
||||||||||||||||||||||||||
MacKay,
Daniel P
|
18,015
|
*
|
3,603
|
-
|
3,603
|
2
|
14,412
|
*
|
||||||||||||||||||||||||||
Madsen,
James L.
|
166,706
|
1.25
|
%
|
27,130
|
-
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
27,130
|
1
|
139,576
|
1.60
|
%
|
||||||||||||||||||||
Majchrowski,
Thomas
|
75,401
|
*
|
15,080
|
-
|
15,080
|
1
|
60,321
|
*
|
||||||||||||||||||||||||||
Marlin
Hull LLC (Michael Huls)
|
179,422
|
1.34
|
%
|
179,422
|
-
|
179,422
|
6
|
0
|
*
|
|||||||||||||||||||||||||
Martin,
Leslie A
|
14,218
|
*
|
2,844
|
2,844
|
2
|
11,374
|
*
|
|||||||||||||||||||||||||||
Matsock,
Mark
|
113,721
|
*
|
10,950
|
25,271
|
$
|
4.15
|
7/15/2005
|
7/15/2007
|
36,221
|
3,6
|
77,500
|
*
|
||||||||||||||||||||||
McInnis,
Greg and Cynthia Family Trust
|
7,229
|
*
|
7,228
|
-
|
7,228
|
4
|
1
|
*
|
||||||||||||||||||||||||||
McKenna,
Jean
|
16,260
|
*
|
3,252
|
-
|
3,252
|
2
|
13,008
|
*
|
||||||||||||||||||||||||||
Mebesius,
William
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Meyers
Associates LP (10)
|
47,828
|
*
|
14,674
|
$
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
14,674
|
6
|
33,154
|
*
|
|||||||||||||||||||||||
Miller,
Thomas F.
|
289,159
|
2.16
|
%
|
289,159
|
-
|
289,159
|
5
|
0
|
*
|
|||||||||||||||||||||||||
Moore,
Terry R
|
15,426
|
*
|
7,464
|
-
|
7,464
|
2
|
7,962
|
*
|
||||||||||||||||||||||||||
Moseley,
Gerard F.
|
9,526
|
*
|
1,905
|
-
|
1,905
|
2
|
7,621
|
*
|
||||||||||||||||||||||||||
Moss,
Lynette F.
|
44,438
|
*
|
15,249
|
-
|
15,249
|
4,8
|
29,189
|
*
|
||||||||||||||||||||||||||
Mountain
View Asset Management (Andrew Eccleston)
|
24,096
|
*
|
24,096
|
-
|
24,096
|
4
|
0
|
*
|
||||||||||||||||||||||||||
MountainView
Opportunistic Growth Fund LP (Andrew Eccleston)
|
94,223
|
*
|
30,745
|
-
|
30,745
|
3,8
|
63,478
|
*
|
||||||||||||||||||||||||||
Muldoon,
William G and Janet L
|
126,854
|
*
|
26,022
|
2,488
|
$
|
1.06
|
2/28/2005
|
2/28/2007
|
28,510
|
2,3
|
98,344
|
1.13
|
%
|
Murphy,
Tom
|
3,369
|
*
|
674
|
-
|
674
|
8
|
2,695
|
*
|
||||||||||||||||||||||||||
Newman,
Bruce W. & Jeannie G.
|
16,587
|
*
|
3,318
|
-
|
3,318
|
2
|
13,269
|
*
|
||||||||||||||||||||||||||
Nichols,
Dale and Kathyrn E. Kaser
|
17,772
|
*
|
3,554
|
-
|
3,554
|
2
|
14,218
|
*
|
||||||||||||||||||||||||||
Oak
Ridge Financial Group Inc. (10)
|
3,285
|
*
|
3,285
|
$
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
3,285
|
6
|
0
|
*
|
|||||||||||||||||||||||
Oliver,
Marlene
|
58,322
|
*
|
44,002
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
44,002
|
1
|
14,320
|
*
|
|||||||||||||||||||||||
Olson,
Claire A & Mary Ann
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Onwuegbusi,
Charles
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Ott,
Suzann J & Dennis L.
|
40,546
|
*
|
7,109
|
-
|
7,109
|
2
|
33,437
|
*
|
||||||||||||||||||||||||||
Palitz,
Louis and Ruth
|
17,772
|
*
|
3,554
|
-
|
3,554
|
2
|
14,218
|
*
|
||||||||||||||||||||||||||
Peterson,
Jerry
|
38,326
|
*
|
38,326
|
-
|
38,326
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Pinnacle
International Holdings LLC (Cliff Aaron)
|
177,736
|
1.33
|
%
|
7,109
|
28,438
|
$
|
0.70
|
11/29/2005
|
10/30/2006
- 03/30/2007
|
35,547
|
2,6
|
142,189
|
1.63
|
%
|
||||||||||||||||||||
Press,
Richard
|
227,652
|
1.70
|
%
|
45,530
|
-
|
45,530
|
1,6
|
182,122
|
2.09
|
%
|
||||||||||||||||||||||||
Quatsch
Ventures, LLC (Stephen Boatwright)
(5)
|
84,236
|
*
|
84,236
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
84,236
|
6
|
0
|
*
|
|||||||||||||||||||||||
Reynolds,
J. Scott
|
6,024
|
*
|
6,024
|
-
|
6,024
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Roberts,
Cory B.
|
1,263
|
*
|
253
|
-
|
253
|
2
|
1,010
|
*
|
||||||||||||||||||||||||||
Roberts,
Donald
|
4,211
|
*
|
842
|
-
|
842
|
2
|
3,369
|
*
|
||||||||||||||||||||||||||
Roberts,
Elizabeth
|
1,263
|
*
|
253
|
-
|
253
|
2
|
1,010
|
*
|
||||||||||||||||||||||||||
Roberts,
Joshua
|
2,947
|
*
|
589
|
-
|
589
|
2
|
2,358
|
*
|
||||||||||||||||||||||||||
Roberts,
Leslie and Rex Armstrong
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Rogers,
Philip and Stephanie(9)
|
8,245
|
*
|
8,245
|
-
|
8,245
|
5
|
0
|
*
|
||||||||||||||||||||||||||
Roman,
Patrick and Nichole
|
1,052
|
*
|
210
|
-
|
210
|
8
|
842
|
*
|
||||||||||||||||||||||||||
Ronald
L and Susan R. Kathren Trust
|
5,171
|
*
|
5,170
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
5,170
|
1
|
1
|
*
|
|||||||||||||||||||||||
Root,
R. William, Jr.
|
176,157
|
1.32
|
%
|
37,131
|
-
|
37,131
|
1,3
|
139,026
|
1.59
|
%
|
||||||||||||||||||||||||
Roozen,
Richard and Jaynie
|
5,474
|
*
|
5,474
|
-
|
5,474
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Rothstein,
Alan F.
|
35,546
|
*
|
7,109
|
-
|
7,109
|
2
|
28,437
|
*
|
||||||||||||||||||||||||||
Rothstein,
Lawrence R. and Deborah E.
|
74,096
|
*
|
24,096
|
-
|
24,096
|
3
|
50,000
|
*
|
||||||||||||||||||||||||||
Rowland,
Chris C.
|
10,475
|
*
|
5,475
|
-
|
5,475
|
3
|
5,000
|
*
|
||||||||||||||||||||||||||
Rowland,
Joseph Perry Jr.
|
5,475
|
*
|
5,475
|
-
|
5,475
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Ruth
Schwartz Trust
|
60,716
|
*
|
12,143
|
-
|
12,143
|
2
|
48,573
|
*
|
||||||||||||||||||||||||||
Safdi
Investments Limited Partnership (Rosemary Safdi)
|
62,921
|
*
|
34,484
|
-
|
34,484
|
2,3
|
28,437
|
*
|
||||||||||||||||||||||||||
Saito,
Dr. Robert N.
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Sanders
Family Limited Partnership III (Vernon Sanders)
|
54,166
|
*
|
20,472
|
-
|
20,472
|
4,8
|
33,694
|
*
|
||||||||||||||||||||||||||
Scallen,
Thomas K.
(9)
|
329,942
|
2.47
|
%
|
329,942
|
-
|
329,942
|
5
|
0
|
*
|
|||||||||||||||||||||||||
Schatzmair,
Ralph
|
46,057
|
*
|
4,211
|
-
|
4,211
|
8
|
41,846
|
*
|
||||||||||||||||||||||||||
Schenter,
Robert
|
218,860
|
1.64
|
%
|
35,489
|
41,416
|
$
|
1.19
|
8/1/2005
|
7/31/2015
|
76,905
|
1
|
141,955
|
1.63
|
%
|
||||||||||||||||||||
Schipfer,
John D., Jr.
|
5,263
|
*
|
1,053
|
-
|
1,053
|
8
|
4,210
|
*
|
||||||||||||||||||||||||||
Schloz
Family 1998 Trust
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Schloz,
Stanley
|
33,000
|
*
|
33,000
|
-
|
33,000
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Schreifels,
Donald B
|
140,943
|
1.05
|
%
|
27,465
|
-
|
27,465
|
4,8
|
113,478
|
1.30
|
%
|
||||||||||||||||||||||||
Schwartz,
Jacob
|
15,950
|
*
|
10,950
|
-
|
10,950
|
3
|
5,000
|
*
|
||||||||||||||||||||||||||
Segna,
Donald R & Joan F. (6)
|
511,213
|
3.82
|
%
|
96,515(7
|
)
|
-
|
96,515
|
1
|
414,698
|
4.75
|
%
|
|||||||||||||||||||||||
Segna,
Jan M
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Segna,
Todd D. & Deborah L.J. Chew
|
21,327
|
*
|
4,265
|
-
|
4,265
|
2
|
17,062
|
*
|
||||||||||||||||||||||||||
Selma
Teicher Trust, Stuart Teicher, Trustee
|
4,819
|
*
|
4,819
|
-
|
4,819
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Shukov,
George
|
227,652
|
1.70
|
%
|
45,530
|
-
|
45,530
|
1,6
|
182,122
|
2.09
|
%
|
||||||||||||||||||||||||
Siddall,
John W.
|
104,752
|
*
|
54,752
|
-
|
54,752
|
3
|
50,000
|
*
|
||||||||||||||||||||||||||
Sidibe,
Aissata
|
35,546
|
*
|
7,109
|
7,109
|
2
|
28,437
|
*
|
Silverman,
Anthony
|
763,961
|
5.72
|
%
|
367,570(8
|
)
|
139,391
|
$
|
4.15
|
7/15/2005
|
7/15/2007
|
506,961
|
3,5,6
|
257,000
|
2.94
|
%
|
|||||||||||||||||||
Silverman,
Anthony IRA Rollover
|
54,753
|
*
|
54,753
|
-
|
54,753
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Silverman,
Jeff
|
72,776
|
*
|
6,110
|
$
|
.59
- 2.37
|
3/25/2005
|
3/25/2007
|
6,110
|
6
|
66,666
|
*
|
|||||||||||||||||||||||
Silverman,
Kay
|
24,096
|
*
|
24,096
|
-
|
24,096
|
4
|
0
|
*
|
||||||||||||||||||||||||||
Silverman,
Kay S. Revocable Trust
|
32,851
|
*
|
32,851
|
-
|
32,851
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Smith,
Albert(5)
|
171,447
|
1.28
|
%
|
21,789
|
12,500
|
$
|
0.0008
|
10/14/2005
|
10/13/2007
|
34,289
|
6,8
|
137,158
|
1.57
|
%
|
||||||||||||||||||||
Source
Capital Group(10)
|
10,584
|
*
|
1,084
|
$
|
0.59
- 2.37
|
3/25/2005
|
3/25/2007
|
1,084
|
6
|
9,500
|
*
|
|||||||||||||||||||||||
Stack,
Peter R and Judy J
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Stealth
Investments, Inc. (James Scannell)
|
44,876
|
*
|
27,376
|
-
|
27,376
|
3
|
17,500
|
*
|
||||||||||||||||||||||||||
Stenson,
Calvin B.
|
8,423
|
*
|
1,685
|
-
|
1,685
|
8
|
6,738
|
*
|
||||||||||||||||||||||||||
Sterne
Agee and Leach, Inc. C/F Jill Ryan IRA
|
5,474
|
*
|
5,474
|
-
|
5,474
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Sterne
Agee and Leach, Inc. C/F Robert Ryan IRA
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Sterne
Agee Leach FBO Barry K Griffith IRA
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Stewart,
James P. and Patricia A.
|
10,950
|
*
|
10,950
|
-
|
10,950
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Stiller,
David L & Bonita L.
|
54,740
|
*
|
10,451
|
498
|
$
|
1.06
|
2/28/2005
|
2/28/2007
|
10,949
|
2
|
43,792
|
*
|
||||||||||||||||||||||
Stokes,
William J.
|
78,052
|
*
|
15,610
|
-
|
15,610
|
1
|
62,442
|
*
|
||||||||||||||||||||||||||
Strain,
Audrey
|
4,975
|
*
|
995
|
-
|
995
|
2
|
3,980
|
*
|
||||||||||||||||||||||||||
Swanberg,
Daniel L. & Joni A.
|
9,479
|
*
|
1,896
|
-
|
1,896
|
2
|
7,583
|
*
|
||||||||||||||||||||||||||
Swanberg,
David J. & Janet C.
(5) (6)
|
448,827
|
3.36
|
%
|
58,047(7
|
)
|
-
|
58,047
|
1,2
|
390,780
|
4.48
|
%
|
|||||||||||||||||||||||
The
Alan Gess Living Trust
|
36,327
|
*
|
4,265
|
-
|
4,265
|
2
|
32,062
|
*
|
||||||||||||||||||||||||||
The
Anderson Family Trust UTD 12/20/93
|
21,059
|
*
|
4,212
|
-
|
4,212
|
8
|
16,847
|
*
|
||||||||||||||||||||||||||
The
Bates Revocable Trust, Fred and Linda Bates, Trustees
|
37,144
|
*
|
6,283
|
-
|
6,283
|
2
|
30,861
|
*
|
||||||||||||||||||||||||||
The
Lanzer Revocable Living Trust
|
18,072
|
*
|
18,072
|
-
|
18,072
|
3
|
0
|
*
|
||||||||||||||||||||||||||
The
Nancy R. McCormick Family Trust U/A dated June 14,2002, John E
McCormick,
Trustee
|
4,819
|
*
|
4,819
|
-
|
4,819.
|
2
|
0
|
*
|
||||||||||||||||||||||||||
The
Smart Family Trust
|
15,450
|
*
|
6,469
|
-
|
6,469
|
2
|
8,981
|
*
|
||||||||||||||||||||||||||
Thomas,
Cam
|
56,875
|
*
|
11,375
|
-
|
11,375
|
2
|
45,500
|
*
|
||||||||||||||||||||||||||
Thompson,
April
|
4,975
|
*
|
995
|
-
|
995
|
2
|
3,980
|
*
|
||||||||||||||||||||||||||
Thompson,
Randy
|
4,975
|
*
|
995
|
-
|
995
|
2
|
3,980
|
*
|
||||||||||||||||||||||||||
Thompson,
William and Karen Trust (6)
|
14,218
|
*
|
2,844
|
2,844
|
2
|
11,374
|
*
|
|||||||||||||||||||||||||||
Turchetta,
Anthony J
|
14,218
|
*
|
2,844
|
-
|
2,844
|
2
|
11,374
|
*
|
||||||||||||||||||||||||||
Turnbull,
Timothy L.
|
8,530
|
*
|
1,706
|
-
|
1,706
|
2
|
6,824
|
*
|
||||||||||||||||||||||||||
UBS
Financial Services IRA FBO Robert R Kauffman (5)
|
32,851
|
*
|
32,851
|
-
|
32,851
|
3
|
0
|
*
|
||||||||||||||||||||||||||
Vencore
LLC
|
5,692
|
*
|
5,692
|
$
|
4.15
|
5/10/2004
|
5/10/2008
|
5,692
|
6
|
0
|
*
|
|||||||||||||||||||||||
Weber,
Ronald
|
4,211
|
*
|
842
|
-
|
842
|
8
|
3,369
|
*
|
||||||||||||||||||||||||||
Weinstein,
Ronald A 2004 Living Trust
|
9,479
|
*
|
1,896
|
-
|
1,896
|
2
|
7,583
|
*
|
||||||||||||||||||||||||||
Weinstein,
Ronald Alan and Cathy Lynn
|
99,765
|
*
|
9,953
|
-
|
9,953
|
2
|
89,812
|
1.03
|
%
|
|||||||||||||||||||||||||
West,
Ron H.
|
4,211
|
*
|
842
|
-
|
842
|
8
|
3,369
|
*
|
||||||||||||||||||||||||||
Whalen,
Ryan and Jennifer
|
1,052
|
*
|
210
|
-
|
210
|
8
|
842
|
*
|
||||||||||||||||||||||||||
Wilkie,
David J
|
8,423
|
*
|
1,685
|
-
|
1,685
|
8
|
6,738
|
*
|
||||||||||||||||||||||||||
William
Wesley Thompson & Karen Louise Thompson
Revocable
Trust Dated January 6, 1999 (6)
|
21,464
|
*
|
4,293
|
-
|
4,293
|
2
|
17,171
|
*
|
||||||||||||||||||||||||||
Wynnjam
Corp. (Michael Huls)
|
107,057
|
*
|
10,950
|
96,107
|
$
|
4.15
|
7/15/2005
|
7/15/2007
|
107,057
|
3,6
|
0
|
*
|
||||||||||||||||||||||
Zaragosa,
Ernesto
|
26,847
|
*
|
16,847
|
$
|
4.15
|
7/15/2005
|
7/15/2007
|
16,847
|
6
|
10,000
|
*
|
|||||||||||||||||||||||
Zielke,
David C. and Diane M.
|
34,123
|
*
|
6,825
|
-
|
6,825
|
2
|
27,298
|
*
|
||||||||||||||||||||||||||
Zimmerman,
Paul
|
21,327
|
*
|
4,265
|
-
|
4,265
|
2
|
17,062
|
*
|
||||||||||||||||||||||||||
Totals
|
13,365,905
|
73.66
|
%
|
4,004,264
|
632,835
|
4,637,100
|
8,728,806
|
70.73
|
%
|
*
|
Less
than one percent.
|
(1)
|
The
number and percentage of shares beneficially owned is determined
in
accordance with Rule 13d-3 of the Securities Exchange Act of 1934,
as
amended, and the information is not necessarily indicative of beneficial
ownership for any other purpose. Under such rule, beneficial ownership
includes any shares as to which the selling shareholder has sole
or shared
voting power or investment power and also any shares that the selling
shareholder has the right to acquire within 60 days.
|
(2)
|
The
actual number of shares of common stock offered in this prospectus,
and
included in the registration statement of which this prospectus is
a part,
includes such additional number of shares of common stock as may
be issued
or issuable upon conversion of the preferred stock and exercise of
the
options and warrants, as applicable, by reason of any stock split,
stock
dividend or similar transaction involving the common stock, in accordance
with Rule 416 under the Securities Act of 1933, as amended.
|
(3)
|
This
column includes all shares of common stock issuable upon conversion
of
preferred stock and exercise of options and warrants, as applicable,
held
by the named selling shareholder.
|
(4)
|
Assumes
that all securities registered will be sold.
|
(5)
|
These
selling shareholders are our executive officers and directors, or
are
entities controlled by our executive officers and
directors.
|
(6)
|
These
selling shareholders are executive officers and directors of our
subsidiary, or are entities controlled by the executive officers
and
directors of our subsidiary.
|
(7)
|
Indicates
shares subject to lock-up through July 28, 2006.
|
(8)
|
233,333
of these shares are subject to lock-up through July 28, 2006.
|
(9)
|
These
selling shareholders are our former executive officers and
directors.
|
(10)
|
These
selling shareholders are broker/dealers or affiliates of
broker/dealers.
|
(1)
|
Founder
shares
|
(2)
|
Shares
purchased in IsoRay Products LLC 10/15/03 PPM
|
(3)
|
Shares
purchased in IsoRay, Medical, Inc. 10/15/04
|
(4)
|
Shares
received for conversion of debenture investment in IsoRay Medical,
Inc.
01/31/05 PPM
|
(5)
|
Certain
Century Park Pictures Corp. shareholders who held shares for many
years
prior to merger with IsoRay Medical, Inc.
|
(6)
|
Equity
received in exchange for services rendered or goods provided to
IsoRay
companies
|
(7)
|
Shares
received through exercise of options or warrants
|
((8)
|
Shares
purchased from founders in the summer of
2005
|
·
|
ordinary
brokers' transactions,
|
·
|
through
brokers, dealers, or underwriters who may act solely as agents,
|
·
|
"at
the market" into an existing market for the common stock,
|
·
|
in
other ways not involving market makers or established trading markets,
including direct sales to purchasers or sales effected through
agents,
|
·
|
in
privately negotiated transactions, and
|
·
|
any
combination of the foregoing.
|
·
|
1,000,000
shares of Series A are authorized and 5,000,000 shares of Series
B are
authorized. As of April 25, 2006 there were no shares of Series
A issued
and outstanding; there were 181,248 Series B preferred shares issued
and
outstanding. The Company has no plans to issue any Series A shares
for the
foreseeable future.
|
·
|
The
Series A shares are entitled to a 10% dividend annually on the
stated
value per share ($1.20) of the Series A, while the Series B shares
are
entitled to a cumulative 15% dividend annually on the stated value
per
share ($1.20) of the Series B. Such dividends will be declared
and paid at
the discretion of the Board to the extent funds are legally available
for
the payment of dividends.
|
·
|
Both
series of preferred shares vote equally with the common stock,
with each
share of preferred having the number of votes equal to the voting
power of
one share of common stock, except that the vote or written consent
of a
majority of the outstanding preferred shares is required for any
changes
to the Company’s Articles of Incorporation, Bylaws or Certificate of
Designation or for any bankruptcy, insolvency, dissolution or liquidation
of the company.
|
·
|
Shares
of either series of preferred stock may be converted at the option
of the
holder into shares of common stock at a rate of one share of common
stock
for each share of preferred stock being converted, subject to adjustment
for stock splits, stock combinations, reorganization, merger,
consolidation, reclassification, exchange or
substitution.
|
·
|
Both
series of preferred stock are subject to automatic conversion into
common
stock upon the closing of a firmly underwritten public offering
pursuant
to an effective registration statement under the Act, covering
the offer
and sale of common stock in which the gross proceeds to the Company
are at
least $4 million.
|
·
|
The
Board of Directors has approved the cancellation of the Series
A Preferred
Stock, given that there are no Series A shares issued, and this
cancellation will occur in the near future. The Board of Directors
has no
plans at this time to issue additional series of preferred stock.
|
Page | |||
Report
of Registered Independent Certified Public Accounting Firm
|
F-2
|
||
Financial
Statements
|
|||
|
|||
Balance
Sheets as of June 30, 2005, September 30, 2004 and 2003
|
F-3
|
||
|
|||
Statements
of Operations and Comprehensive Income (Loss) for the nine months
ended June 30, 2005 and for the years ended September 30, 2004
and 2003
|
F-4
|
||
|
|||
Statement
of Changes in Shareholders' Equity for the nine months ended June
30, 2005 and for the years ended September 30, 2004 and 2003
|
F-5
|
||
|
|||
Statements
of Cash Flows for the nine months ended June 30, 2005 and for the
years ended September 30, 2004 and 2003
|
F-6
|
||
Notes
to Financial Statements
|
F-7
|
||
Unaudited
Financial Statements
|
F-20
|
||
Consolidated
Balance Sheets as of December 31, 2005
|
F-21
|
||
|
|||
Consolidated
Statements of Operations for the six months ended December 31,
2005
|
F-22
|
||
Consolidated
Statements of Cash Flows for the six months ended December 31,
2005
|
F-23
|
||
Notes
to Financial Statements
|
F-24
|
June
30,
2005
|
September
30,
2004
|
September
30, 2003
|
||||||||
Assets
|
||||||||||
Current
Assets
|
||||||||||
Cash
on
hand and in bank
|
$
|
32,587
|
$
|
-
|
$
|
-
|
||||
Total
current assets
|
32,587
|
-
|
-
|
|||||||
Other
Assets
|
-
|
926
|
926
|
|||||||
Rent
deposits
|
||||||||||
Total
Assets
|
$
|
32,587
|
$
|
926
|
$
|
926
|
||||
Current
Liabilities
|
||||||||||
Notes
payable
|
$
|
-
|
$
|
-
|
$
|
100,000
|
||||
Accounts
payable - trade
|
21,355
|
395
|
-
|
|||||||
Accrued
officer compensation
|
-
|
354,500
|
354,500
|
|||||||
Accrued
interest payable
|
-
|
-
|
73,714
|
|||||||
Other
accrued expenses
|
-
|
-
|
9,027
|
|||||||
Advances
from shareholder
|
-
|
37,744
|
27,887
|
|||||||
Total
current liabilities
|
21,355
|
392,639
|
565,128
|
|||||||
Shareholders'
Equity (Deficit)
|
||||||||||
Preferred
stock - $0.001 par value
|
||||||||||
6,000,000
shares authorized
|
||||||||||
1,000,000
shares allocated to Series A
|
-
|
-
|
-
|
|||||||
5,000,000
shares allocated to Series B
|
-
|
-
|
-
|
|||||||
Common
stock - $0.001 par value.
|
||||||||||
194,000,000
shares authorized.
|
||||||||||
2,498,319,
2,414,985 and 2,099,554 shares issued
and outstanding, respectively
|
2,498
|
2,415
|
2,099
|
|||||||
Additional
paid-in capital
|
7,307,600
|
6,874,610
|
6,778,194
|
|||||||
Accumulated
deficit
|
(7,298,866
|
)
|
(7,268,738
|
)
|
(7,344,495
|
)
|
||||
Total
shareholders' equity (deficit)
|
11,232
|
(391,713
|
)
|
(564,202
|
)
|
|||||
Total
Liabilities and Shareholders'
Equity (Deficit)
|
$
|
32,587
|
$
|
926
|
$
|
926
|
Nine
months
ended
June
30,
2005
|
Year
ended
September
30,
2004
|
Year
ended
September
30,
2003
|
||||||||
Revenues
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Expenses
|
||||||||||
General
and administrative expenses
|
30,128
|
9,095
|
19,022
|
|||||||
Statutory
cancellation of notes payable and accrued interest
|
-
|
(86,956
|
)
|
-
|
||||||
Total
expenses
|
30,128
|
(77,861
|
)
|
-
|
||||||
Income
(Loss) from operations
|
(30,128
|
)
|
(77,861
|
)
|
(19,022
|
)
|
||||
Other
Expense
|
||||||||||
Interest
expense
|
-
|
(2,104
|
)
|
(41,005
|
)
|
|||||
Income
(Loss) before provision for
income taxes and extraordinary item
|
(30,128
|
)
|
75,757
|
(60,027
|
)
|
|||||
Provision
for income taxes
|
-
|
-
|
-
|
|||||||
Net
Income (Loss)
|
(30,128
|
)
|
75,757
|
(60,027
|
)
|
|||||
Other
Comprehensive Income
|
-
|
-
|
-
|
|||||||
Comprehensive
Income (Loss)
|
$
|
(30,128
|
)
|
$
|
75,757
|
$
|
(60,027
|
)
|
||
Income
(Loss) per weighted-average share
of common stock outstanding, computed
on Net Loss - basic and fully diluted
|
$
|
(0.01
|
)
|
$
|
(0.03
|
)
|
$
|
(0.07
|
)
|
|
Weighted-average
number of shares of
common stock outstanding
|
2,429,027
|
2,360,690
|
804,619
|
Common
Stock
|
||||||||||||||||
Shares
|
Amount
|
Additional paid-in
capital
|
Accumulated
deficit
|
Total
|
||||||||||||
Balances
at October 1, 2002
|
9,886,641
|
$
|
9,887
|
$
|
6,191,566
|
$
|
(7,284,468
|
)
|
$
|
(1,083,015
|
)
|
|||||
Effect
of April 29, 2005 1-for-30
reverse stock split
|
(9,557,317
|
)
|
(9,558
|
)
|
9,558
|
-
|
-
|
|||||||||
Balances
at October
1, 2002, as reset
|
329,324
|
329
|
6,201,124
|
(7,284,468
|
)
|
(1,083,015
|
)
|
|||||||||
Conversion
of notes payable and
accrued interest payable to
common stock
|
1,770,230
|
1,770
|
529,299
|
-
|
531,069
|
|||||||||||
Forgiveness
of accrued interest
|
-
|
-
|
6,766
|
-
|
6,766
|
|||||||||||
Contribution
of imputed interest on
suspended interest on notes
payable
|
-
|
-
|
41,005
|
-
|
41,005
|
|||||||||||
Net
loss for the year
|
-
|
-
|
-
|
(60,027
|
)
|
(60,027
|
)
|
|||||||||
Balances
at September
30, 2003
|
2,099,554
|
2,099
|
6,778,194
|
(7,344,495
|
)
|
(564,202
|
)
|
|||||||||
Conversion
of notes payable and
accrued interest payable to
common stock
|
289,194
|
290
|
86,468
|
-
|
86,758
|
|||||||||||
Contribution
of imputed interest on suspended
interest on notes payable
|
-
|
-
|
2,104
|
-
|
2,104
|
|||||||||||
Common
stock issued for debt
conversion services
|
26,237
|
26
|
7,844
|
-
|
7,870
|
|||||||||||
Net
income for the year
|
-
|
-
|
-
|
75,757
|
75,757
|
|||||||||||
Balances
at September
30, 2004
|
2,414,985
|
2,415
|
6,874,610
|
(7,268,738
|
)
|
(391,713
|
)
|
|||||||||
Sale
of common stock for
cash
|
83,334
|
83
|
84,917
|
-
|
85,000
|
|||||||||||
Contributed
capital
|
-
|
-
|
43,573
|
-
|
43,573
|
|||||||||||
Contribution
of forgiven accrued
officer's compensation
|
-
|
-
|
304,500
|
-
|
304,500
|
|||||||||||
Net
income for the nine months
|
-
|
-
|
-
|
(30,128
|
)
|
(30,128
|
)
|
|||||||||
Balances
at June
30, 2005
|
2,498,319
|
$
|
2,498
|
$
|
7,307,600
|
$
|
(7,298,866
|
)
|
$
|
11,232
|
Nine
months
ended
June
30,
2005
|
Year
ended
September
30,
2004
|
Year
ended
September 30,
2003
|
||||||||
Cash
Flows from Operating Activities
|
||||||||||
Net
Income (Loss)
|
$
|
(30,128
|
)
|
$
|
75,757
|
$
|
(60,027
|
)
|
||
Adjustments
to reconcile net income to net cash provided
by operating activities
|
||||||||||
Extinguishment
of notes payable and accrued interest
|
-
|
(86,956
|
)
|
-
|
||||||
Consulting
fees paid with common stock
|
-
|
7,870
|
-
|
|||||||
Contribution
of interest expense related to suspended
interest payable on notes payable
|
-
|
2,104
|
41,005
|
|||||||
Increase
(Decrease) in Accounts
payable and other accrued expenses
|
(29,040
|
)
|
(8,632
|
)
|
-
|
|||||
Net
cash used in operating activities
|
(59,168
|
)
|
(9,857
|
)
|
(19,022
|
)
|
||||
Cash
Flows from Investing Activities
|
-
|
-
|
-
|
|||||||
Cash
Flows from Financing Activities
|
||||||||||
Proceeds
from sale of common stock
|
85,000
|
-
|
-
|
|||||||
Funds
advanced by officer/shareholder
|
6,735
|
9,857
|
19,022
|
|||||||
Net
cash provided by financing activities
|
91,755
|
9,857
|
19,022
|
|||||||
Increase
(Decrease) in Cash and Cash Equivalents
|
32,587
|
-
|
-
|
|||||||
Cash
and cash equivalents at beginning of period
|
-
|
-
|
-
|
|||||||
Cash
and cash equivalents at end of period
|
$
|
32,587
|
$
|
-
|
$
|
-
|
||||
Supplemental
Disclosures of Interest and Income
Taxes
Paid
|
||||||||||
Interest
paid during the period
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Income
taxes paid (refunded)
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Supplemental
Disclosure of Non-cash Investing
and
Financing Activities
|
||||||||||
Conversion
of forgiven unpaid accrued officers compensation
to accrued capital
|
$
|
304,500
|
$
|
-
|
$
|
-
|
Nine
months
ended
June 30,
2005
|
Year
ended
September
30,
2004
|
Year
ended September 30,
2003
|
||||||||
Federal:
|
||||||||||
Current
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Deferred
|
-
|
-
|
-
|
|||||||
|
- |
-
|
-
|
|||||||
State:
|
||||||||||
Current
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Deferred
|
-
|
-
|
-
|
|||||||
|
- |
-
|
-
|
|||||||
Total
|
$
|
-
|
$
|
-
|
$
|
-
|
Nine
months
ended
June 30,
2005
|
Year
ended
September
30,
2004
|
Year
ended September 30,
2003
|
||||||||
Statutory
rate applied to earnings (loss) before income taxes
|
$
|
10,200
|
$
|
25,750
|
$
|
(20,400
|
)
|
|||
Increase
(decrease) in income taxes resulting from:
|
||||||||||
State
income taxes
|
-
|
-
|
-
|
|||||||
Other,
including reserve for deferred tax asset
|
(10,200
|
)
|
(25,750
|
)
|
20,400
|
|||||
Income
tax expense
|
$
|
-
|
$
|
-
|
$
|
-
|
Nine
months ended June 30, 2005
|
||||||||||
Federal
|
State
|
Total
|
||||||||
Deferred
tax assets:
|
||||||||||
Other
(current)
|
$
|
96,000
|
$
|
35,000
|
$
|
131,000
|
||||
Net
operating loss carryforwards (non-current)
|
932,000
|
77,000
|
1,009,000
|
|||||||
1,028,000
|
112,000
|
1,140,000
|
||||||||
Valuation
allowance
|
(1,028,000
|
)
|
(112,000
|
)
|
(1,140,000
|
)
|
||||
Net
Deferred tax asset
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Deferred
tax liabilities
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Year
ended September 30, 2004
|
||||||||||
Federal
|
State
|
Total
|
||||||||
Deferred
tax assets:
|
||||||||||
Other
(current)
|
$
|
96,000
|
$
|
35,000
|
$
|
131,000
|
||||
Net
operating loss carryforwards (non-current)
|
932,000
|
77,000
|
1,009,000
|
|||||||
1,028,000
|
112,000
|
1,140,000
|
||||||||
Valuation
allowance
|
(1,028,000
|
)
|
(112,000
|
)
|
(1,140,000
|
)
|
||||
Net
Deferred tax asset
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Deferred
tax liabilities
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
|
Year
ended September 30, 2003
|
|||||||||
Federal
|
State
|
Total
|
||||||||
Deferred
tax assets:
|
||||||||||
Other
(current)
|
$
|
96,000
|
$
|
35,000
|
$
|
131,000
|
||||
Net
operating loss carryforwards (non-current)
|
932,000
|
77,000
|
1,009,000
|
|||||||
1,028,000
|
112,000
|
1,140,000
|
||||||||
Valuation
allowance
|
(1,028,000
|
)
|
(112,000
|
)
|
(1,140,000
|
)
|
||||
Net
Deferred tax asset
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
Deferred
tax liabilities
|
$
|
-
|
$
|
-
|
$
|
-
|
IsoRay, Inc. and Subsidiary | ||||||||||
Consolidated Balance Sheets | ||||||||||
|
(Unaudited)
|
|||||||||
|
December
31,
|
June
30,
|
||||||||
2005
|
2005
|
|||||||||
ASSETS | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 648,684 | $ | 32,587 | ||||||
Accounts receivable, net | 467,616 | - | ||||||||
Inventory | 156,019 | - | ||||||||
Prepaid expenses | 208,942 | |||||||||
Total current assets | 1,481,261 | 32,587 | ||||||||
Fixed assets, net of accumulated depreciation and amortization | 1,627,443 | - | ||||||||
Other assets, net of accumulated amortization | 754,305 | - | ||||||||
Total assets | $ | 3,863,009 | $ | 32,587 | ||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ | 425,048 | $ | 21,355 | ||||||
Accrued payroll and related taxes | 222,958 | - | ||||||||
Accrued interest payable | 83,390 | - | ||||||||
Notes payable, due within one year | 244,219 | - | ||||||||
Capital lease obligations, due within one year | 174,930 | - | ||||||||
Total current liabilities | 1,150,545 | 21,355 | ||||||||
Notes payable, due after one year | 531,194 | - | ||||||||
Capital lease obligations, due after one year | 295,874 | - | ||||||||
Convertible debentures payable, due after one year | 530,000 | - | ||||||||
Total liabilities | 2,507,613 | 21,355 | ||||||||
Shareholders' equity: | ||||||||||
Preferred stock, $.001 par value; 6,000,000 shares authorized: | ||||||||||
Series A: 1,000,000 shares allocated; no shares issued and outstanding | - | - | ||||||||
Series B: 5,000,000 shares allocated; 292,328 and no shares issued and outstanding | 292 | - | ||||||||
Common stock, $.001 par value; 194,000,000 shares authorized; 13,383,139 and | ||||||||||
2,498,319 shares issued and outstanding | 13,383 | 2,498 | ||||||||
Subscriptions receivable (Note 8) | (6,227,067 | ) | - | |||||||
Additional paid-in capital | 16,835,833 | 7,307,600 | ||||||||
Accumulated deficit | (9,267,045 | ) | (7,298,866 | ) | ||||||
Total shareholders' equity | 1,355,396 | 11,232 | ||||||||
Total liabilities and shareholders' equity | $ | 3,863,009 | $ | 32,587 |
IsoRay,
Inc and Subsidiary
|
|||||||||||||
Consolidated
Statements of Operations
|
|||||||||||||
Three
and Six Months Ended December 31, 2005 and 2004 (Unaudited)
|
|||||||||||||
For
the three months ended
|
For
the six months ended
|
||||||||||||
December
31,
|
December
31,
|
December
31,
|
December
31,
|
||||||||||
2005
|
2004
|
2005
|
2004
|
||||||||||
Product
sales
|
$
|
486,247
|
$
|
-
|
$
|
697,162
|
$
|
-
|
|||||
Cost
of product sales
|
916,274
|
-
|
1,636,440
|
-
|
|||||||||
Gross
profit (loss)
|
(430,027
|
)
|
-
|
(939,278
|
)
|
-
|
|||||||
Operating
expenses:
|
|||||||||||||
Research
and development
|
96,837
|
-
|
122,619
|
-
|
|||||||||
Sales
and marketing expenses
|
340,532
|
-
|
655,571
|
-
|
|||||||||
General
and administrative expenses
|
675,444
|
3,574
|
1,636,393
|
7,743
|
|||||||||
Total
operating expenses
|
1,112,813
|
3,574
|
2,414,583
|
7,743
|
|||||||||
Operating
loss
|
(1,542,840
|
)
|
(3,574
|
)
|
(3,353,861
|
)
|
(7,743
|
)
|
|||||
Non-operating
income (expense):
|
|||||||||||||
Interest
income
|
3,193
|
-
|
10,152
|
-
|
|||||||||
Financing
expense
|
(195,480
|
)
|
-
|
(351,108
|
)
|
-
|
|||||||
Debt
conversion expense (Note 7)
|
(244,097
|
)
|
-
|
(244,097
|
)
|
-
|
|||||||
Non-operating
income (expense), net
|
(436,384
|
)
|
-
|
(585,053
|
)
|
-
|
|||||||
Net
loss
|
$
|
(1,979,224
|
)
|
$
|
(3,574
|
)
|
$
|
(3,938,914
|
)
|
$
|
(7,743
|
)
|
|
Net
loss per weighted-average share of common stock
|
$
|
(0.17
|
)
|
$
|
(0.00
|
)
|
$
|
(0.36
|
)
|
$
|
(0.00
|
)
|
|
Basic
weighted average shares outstanding
|
11,852,047
|
2,415,214
|
10,844,913
|
2,415,214
|
IsoRay,
Inc. and Subsidiary
|
|||||||
Consolidated
Statements of Cash Flows
|
|||||||
Six
Months Ended December 31, 2005 and 2004 (Unaudited)
|
|||||||
For
the six months ended
|
|||||||
December
31,
|
December
31,
|
||||||
2005
|
2004
|
||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|||||||
Net
loss
|
$
|
(3,938,914
|
)
|
$
|
(7,743
|
)
|
|
Adjustments
to reconcile net loss to net cash used by operating activities:
|
|||||||
Depreciation
and amortization of fixed assets
|
95,432
|
-
|
|||||
Amortization
of
deferred financing costs and other assets
|
103,546
|
-
|
|||||
Compensation
recorded in connection with issuance of common stock
|
330,000
|
-
|
|||||
Rent
expense paid by issuance of common stock
|
30,009
|
-
|
|||||
Repair
and maintenance expense paid by issuance of common stock
|
14,752
|
-
|
|||||
Debt
conversion expense (Note 7)
|
244,097
|
-
|
|||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable, net
|
(417,647
|
)
|
-
|
||||
Inventory
|
(74,093
|
)
|
-
|
||||
Prepaid
expenses
|
62,350
|
-
|
|||||
Accounts
payable
|
(291,895
|
)
|
(75
|
)
|
|||
Accrued
payroll and related taxes
|
65,032
|
-
|
|||||
Accrued
interest payable
|
42,065
|
-
|
|||||
Other
accrued expenses
|
-
|
395
|
|||||
Net
cash used by operating activities
|
(3,735,266
|
)
|
(7,423
|
)
|
|||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|||||||
Purchases
of fixed assets
|
(347,357
|
)
|
-
|
||||
Additions
to other assets
|
(64,096
|
)
|
-
|
||||
Net
cash used by investing activities
|
(411,453
|
)
|
-
|
||||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
Funds
advanced by officer/shareholder
|
-
|
7,423
|
|||||
Net
advances on line of credit
|
200,000
|
-
|
|||||
Proceeds
from issuance of notes payable
|
250,000
|
-
|
|||||
Proceeds
from sales of convertible debentures payable
|
550,000
|
-
|
|||||
Principal
payments on notes payable
|
(279,926
|
)
|
-
|
||||
Principal
payments on capital lease obligations
|
(66,329
|
)
|
-
|
||||
Proceeds
from cash sales of common stock, net of issuance costs
|
2,324,168
|
-
|
|||||
Proceeds
from cash sales of common stock, pursuant to exercise of warrants
|
59,565
|
-
|
|||||
Proceeds
from cash sales of common stock, pursuant to exercise of options
|
72,928
|
-
|
|||||
Payments
to common shareholders in lieu of issuing fractional shares
|
(734
|
)
|
-
|
||||
Net
cash provided by financing activities
|
3,109,672
|
7,423
|
|||||
Net
decrease in cash and cash equivalents
|
(1,037,047
|
)
|
-
|
||||
Cash
and cash equivalents, beginning of period
|
1,685,731
|
-
|
|||||
CASH
AND CASH EQUIVALENTS, END OF PERIOD
|
$
|
648,684
|
$
|
-
|
|||
Supplemental
disclosures of cash flow information:
|
|||||||
Cash
paid for interest
|
$
|
205,497
|
$
|
-
|
|||
Non-cash
investing and financing activities:
|
|||||||
Exchange
of convertible debentures payable for shares of common stock
|
$
|
3,607,875
|
|||||
Fixed
assets acquired by capital lease obligations
|
$
|
507,947
|
|||||
Prepaid
rent paid by issuance of common stock
|
$
|
90,026
|
|||||
For
the three months ended
|
For
the six months ended
|
||||||||||||
December
31,
2005 |
December
31,
2004 |
December
31,
2005 |
December
31,
2004 |
||||||||||
Net
loss, as reported
|
$
|
(1,979,224
|
)
|
$
|
(3,574
|
)
|
$
|
(3,938,914
|
)
|
$
|
(7,743
|
)
|
|
Less:
Stock-based compensation expense determined under
|
|||||||||||||
fair
value method for all stock options, net of related tax
benefit
|
$
|
(3,254
|
)
|
$
|
-
|
(159,254
|
)
|
$
|
-
|
||||
Profoma
net loss
|
$
|
(1,982,478
|
)
|
$
|
(3,574
|
)
|
$
|
(4,098,168
|
)
|
$
|
(7,743
|
)
|
|
Basic
net loss per common share:
|
|||||||||||||
As
reported
|
$
|
(0.17
|
)
|
$
|
(0.00
|
)
|
$
|
(0.36
|
)
|
$
|
(0.00
|
)
|
|
Proforma
|
$
|
(0.17
|
)
|
$
|
(0.00
|
)
|
$
|
(0.38
|
)
|
$
|
(0.00
|
)
|
|
Diluted
net loss per common share:
|
|||||||||||||
As
reported
|
$
|
(0.17
|
)
|
$
|
(0.00
|
)
|
$
|
(0.36
|
)
|
$
|
(0.00
|
)
|
|
Proforma
|
$
|
(0.17
|
)
|
$
|
(0.00
|
)
|
$
|
(0.38
|
)
|
$
|
(0.00
|
)
|
Page | ||
Report
of Independent Auditor
|
F-30
|
|
Financial
Statements
|
||
|
||
Combined
Balance Sheets as of June 30, 2005 and 2004
|
F-31
|
|
|
||
Combined
Statements of Operations for the years ended June 30, 2005 and
2004
|
F-32
|
|
|
|
|
Combined
Statement of Changes in Shareholders' Equity (Deficit) for the
years ended June 30, 2005 and 2004
|
F-33
|
|
|
|
|
Combined
Statements of Cash Flows for the years ended June 30, 2005 and
2004
|
F-34
|
|
Notes
to Combined Financial Statements
|
F-35
|
IsoRay
Medical, Inc.
Combined
Balance Sheets
June
30, 2005 and 2004
|
|||||||
2005
|
2004
|
||||||
ASSETS
|
|||||||
Current
assets:
|
|||||||
Cash
and cash equivalents (Note 2)
|
$
|
1,653,144
|
$
|
470,439
|
|||
Accounts
receivable, net of allowance for doubtful accounts of $17,075
|
49,969
|
-
|
|||||
Inventory
(Note 5)
|
81,926
|
19,726
|
|||||
Prepaid
expenses (Note 6)
|
181,266
|
77,133
|
|||||
Total
current assets
|
1,966,305
|
567,298
|
|||||
Fixed
assets, net of accumulated depreciation and amortization (Note 7)
|
842,323
|
297,181
|
|||||
Other
assets, net of accumulated amortization (Note 8)
|
793,756
|
96,295
|
|||||
Total
assets
|
$
|
3,602,384
|
$
|
960,774
|
|||
LIABILITIES
AND SHAREHOLDERS' EQUITY (DEFICIT)
|
|||||||
Current
liabilities:
|
|||||||
Accounts
payable
|
$
|
695,588
|
$
|
129,021
|
|||
Accrued
payroll and related taxes
|
157,924
|
58,010
|
|||||
Accrued
interest payable
|
41,325
|
8,235
|
|||||
Other
current liabilities (Note 4)
|
-
|
91,765
|
|||||
Notes
payable, due within one year (Note 10)
|
43,116
|
10,000
|
|||||
Capital
lease obligations, due within one year (Note 11)
|
9,604
|
-
|
|||||
Total
current liabilities
|
947,557
|
297,031
|
|||||
Notes
payable, due after one year (Note 10)
|
562,224
|
350,000
|
|||||
Capital
lease obligations, due after one year (Note 11)
|
19,584
|
-
|
|||||
Convertible
debentures payable, due after one year (Note 12)
|
3,587,875
|
-
|
|||||
Total
liabilities
|
5,117,240
|
647,031
|
|||||
Commitments
and contingencies (Notes 16 and 17)
|
|||||||
Shareholders'
equity (deficit) (Notes 1, 4 and 13):
|
|||||||
Preferred
stock, $.001 par value, 10,000,000 shares authorized:
|
|||||||
Series
A: No shares issued and outstanding
|
-
|
-
|
|||||
Series
B: 1,588,589 and no shares issued and outstanding
|
1,589
|
-
|
|||||
IsoRay
Medical, Inc. common stock, $.001 par value; 100,000,000 shares
authorized; 7,317,073 and 10,000 shares issued and outstanding
|
7,317
|
10
|
|||||
IsoRay,
Inc. common stock , $.001 par value; 20,000,000 shares authorized;
no shares and 2,767,700 shares issued and outstanding
|
-
|
2,768
|
|||||
Additional
paid-in capital
|
3,804,369
|
1,369,908
|
|||||
Accumulated
deficit
|
(5,328,131
|
)
|
(1,058,943
|
)
|
|||
Total
shareholders' equity (deficit)
|
(1,514,856
|
)
|
313,743
|
||||
Total
liabilities and shareholders' equity (deficit)
|
$
|
3,602,384
|
$
|
960,774
|
|||
IsoRay
Medical, Inc.
Combined
Statements of Operations
Years
Ended June 30, 2005 and 2004
|
|||||||
2005
|
2004
|
||||||
Product
sales
|
$
|
201,731
|
$
|
-
|
|||
Cost
of product sales (Note 5)
|
1,474,251
|
-
|
|||||
Gross
profit (loss)
|
(1,272,520
|
)
|
-
|
||||
Operating
expenses:
|
|||||||
Research
and development
|
137,532
|
42,326
|
|||||
Sales
and marketing expenses
|
701,822
|
81,486
|
|||||
General
and administrative expenses
|
1,871,325
|
650,161
|
|||||
Total
operating expenses
|
2,710,679
|
773,973
|
|||||
Operating
loss
|
(3,983,199
|
)
|
(773,973
|
)
|
|||
Non-operating
income (expense):
|
|||||||
Interest
income
|
2,394
|
1,898
|
|||||
Financing
expense (Note 8)
|
(167,493
|
)
|
(23,470
|
)
|
|||
Loss
on disposal of fixed assets
|
(120,890
|
)
|
-
|
||||
Non-operating
income (expense), net
|
(285,989
|
)
|
(21,572
|
)
|
|||
Net
loss
|
$
|
(4,269,188
|
)
|
$
|
(795,545
|
)
|
|
Net
loss per share of common stock
|
$
|
(0.66
|
)
|
$
|
(0.15
|
)
|
|
Basic
weighted average shares outstanding (Note 2)
|
6,493,700
|
5,174,346
|
IsoRay
Medical, Inc.
Combined
Statement of Changes in Shareholders' Equity
(Deficit)
Years
Ended June 30, 2005 and 2004
|
||||||||||||||||||||||||||||
IsoRay,
Inc.
|
IsoRay
Medical, Inc.
|
Additional
|
||||||||||||||||||||||||||
Common
Stock
|
Series
B Preferred Stock
|
Common
Stock
|
Paid-in
|
Accumulated
|
||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
||||||||||||||||||||
Balances
at June 30, 2003
|
2,607,700
|
$
|
2,608
|
-
|
$
|
-
|
-
|
$
|
-
|
$
|
181,642
|
$
|
(263,398
|
)
|
$
|
(79,148
|
)
|
|||||||||||
Issuance
of IsoRay, Inc. common shares as payment
for
prototype laser welding station (Note 13)
|
80,000
|
80
|
79,920
|
80,000
|
||||||||||||||||||||||||
Issuance
of IsoRay, Inc. common shares for cash
|
80,000
|
80
|
79,920
|
80,000
|
||||||||||||||||||||||||
Issuance
of IsoRay Products LLC member shares
for
cash, net of offering costs (Note 4)
|
1,060,201
|
1,060,201
|
||||||||||||||||||||||||||
Accrual
of dividends payable to IsoRay Products LLC
members
(Note 4)
|
(91,765
|
)
|
(91,765
|
)
|
||||||||||||||||||||||||
Issuance
of IsoRay Products LLC member shares and
IsoRay
Medical, Inc. common shares to related
party
for cash and compensation (Note 15)
|
10,000
|
10
|
59,990
|
60,000
|
||||||||||||||||||||||||
Net
loss for the year ended June 30, 2004
|
(795,545
|
)
|
(795,545
|
)
|
||||||||||||||||||||||||
Balances
at June 30, 2004
|
2,767,700
|
2,768
|
-
|
-
|
10,000
|
10
|
1,369,908
|
(1,058,943
|
)
|
313,743
|
||||||||||||||||||
Issuance
of IsoRay, Inc. common shares pursuant to
exercise
of
options (Note 13)
|
71,580
|
71
|
71,509
|
71,580
|
||||||||||||||||||||||||
Issuance
of IsoRay, Inc. common shares as
compensation
(Note 13)
|
57,025
|
57
|
56,968
|
57,025
|
||||||||||||||||||||||||
Issuance
of IsoRay Products LLC member shares for
cash,
net of offering costs (Note 4)
|
303,743
|
303,743
|
||||||||||||||||||||||||||
Merger
transaction (Note 1)
|
(2,896,305
|
)
|
(2,896
|
)
|
1,483,723
|
1,484
|
6,167,426
|
6,167
|
(4,755
|
)
|
-
|
|||||||||||||||||
Reversal
of dividends accrued by IsoRay
Products
LLC
(Note 4)
|
91,765
|
91,765
|
||||||||||||||||||||||||||
Issuance
of IsoRay Medical, Inc. common shares for
cash
pursuant to private placement, net of offering
costs
(Note 4)
|
765,500
|
766
|
1,355,812
|
1,356,578
|
||||||||||||||||||||||||
Issuance
of IsoRay Medical, Inc. common shares
pursuant
to
exercise of warrants granted in
connection
with
private placement (Note
13)
|
129,750
|
130
|
64,745
|
64,875
|
||||||||||||||||||||||||
Issuance
of IsoRay Medical, Inc. common shares as
inducement
for
guarantee of debt (Note 13)
|
211,140
|
211
|
348,170
|
348,381
|
||||||||||||||||||||||||
Issuance
of IsoRay Medical, Inc. common shares as
partial
payment for laser welding stations (Note 13)
|
30,303
|
30
|
49,970
|
50,000
|
||||||||||||||||||||||||
Issuance
of Series B preferred shares pursuant
to
exercise of warrants (Note 13)
|
107,820
|
108
|
96,634
|
96,742
|
||||||||||||||||||||||||
Exchange
of Series B preferred shares for IsoRay
Medical,
Inc.
common shares
|
(2,954
|
)
|
(3
|
)
|
2,954
|
3
|
-
|
|||||||||||||||||||||
Payments
to common shareholders in lieu of issuing
fractional
shares (Note 13)
|
(100
|
)
|
(100
|
)
|
||||||||||||||||||||||||
Net
loss for the year ended June 30, 2005
|
(4,269,188
|
)
|
(4,269,188
|
)
|
||||||||||||||||||||||||
Balances
at June 30, 2005
|
-
|
$
|
-
|
1,588,589
|
$
|
1,589
|
7,317,073
|
$
|
7,317
|
$
|
3,804,369
|
$
|
(5,328,131
|
)
|
$
|
(1,514,856
|
)
|
IsoRay
Medical, Inc.
Combined
Statements of Cash Flows
Years
Ended June 30, 2005 and 2004
|
|||||||
2005
|
2004
|
||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|||||||
Net
loss
|
$
|
(4,269,188
|
)
|
$
|
(795,545
|
)
|
|
Adjustments
to reconcile net loss to net cash used by operating activities:
|
|||||||
Depreciation
and amortization of fixed assets
|
140,099
|
23,233
|
|||||
Amortization
of
deferred financing costs and other assets
|
82,358
|
5,200
|
|||||
Loss
on
disposal of fixed assets
|
120,890
|
-
|
|||||
Compensation
recorded in connection with issuance of common stock
|
57,025
|
59,900
|
|||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable, net
|
(49,969
|
)
|
-
|
||||
Inventory
|
(62,200
|
)
|
(19,726
|
)
|
|||
Prepaid
expenses
|
(104,133
|
)
|
(72,439
|
)
|
|||
Accounts
payable
|
566,567
|
114,958
|
|||||
Accrued
payroll and related taxes
|
99,914
|
58,010
|
|||||
Accrued
interest payable
|
33,090
|
107
|
|||||
Net
cash used by operating activities
|
(3,385,547
|
)
|
(626,302
|
)
|
|||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|||||||
Purchases
of fixed assets
|
(724,029
|
)
|
(167,875
|
)
|
|||
Additions
to other assets
|
(431,438
|
)
|
(70,117
|
)
|
|||
Net
cash used by investing activities
|
(1,155,467
|
)
|
(237,992
|
)
|
|||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
Borrowings
under notes payable
|
315,000
|
330,000
|
|||||
Proceeds
from sales of convertible debentures payable
|
3,587,875
|
-
|
|||||
Principal
payments on notes payable
|
(23,653
|
)
|
(139,803
|
)
|
|||
Principal
payments on capital lease obligations
|
(2,914
|
)
|
-
|
||||
Issuance
of common shares and LLC member shares for cash, net of offering
costs
|
1,847,511
|
1,140,301
|
|||||
Payments
to common and Series B preferred shareholders in lieu of issuing
fractional shares
|
(100
|
)
|
-
|
||||
Net
cash provided by financing activities
|
5,723,719
|
1,330,498
|
|||||
Net
increase in cash and cash equivalents
|
1,182,705
|
466,204
|
|||||
Cash
and cash equivalents, beginning of period
|
470,439
|
4,235
|
|||||
CASH
AND CASH EQUIVALENTS, END OF PERIOD
|
$
|
1,653,144
|
$
|
470,439
|
|||
Supplemental
disclosures of cash flow information:
|
|||||||
Cash
paid for interest
|
$
|
57,657
|
$
|
23,577
|
|||
Non-cash
investing and financing activities:
|
|||||||
Fixed
assets acquired by capital lease obligations
|
$
|
32,102
|
$
|
-
|
|||
Issuance
of
IsoRay Medical, Inc. preferred shares for debt reduction
|
$
|
46,007
|
|||||
Issuance
of
common shares as compensation for guarantee of debt
|
$
|
348,381
|
|||||
Accrual
(reversal) of dividends payable to IsoRay Products LLC members
|
$
|
(91,765
|
)
|
$
|
91,765
|
||
Issuance
of
common shares for laser welding stations purchases
|
$
|
50,000
|
$
|
80,000
|
2005
|
2004
|
||||||
Raw
materials
|
$
|
27,659
|
$
|
19,726
|
|||
Work
in process
|
54,267
|
—
|
|||||
$
|
81,926
|
$
|
19,726
|
2005
|
2004
|
||||||
Prepaid
contract work
|
$
|
65,328
|
$
|
69,063
|
|||
Prepaid
insurance
|
15,853
|
5,350
|
|||||
Other
prepaid expenses
|
100,085
|
2,720
|
|||||
$
|
181,266
|
$
|
77,133
|
2005
|
2004
|
||||||
Production
equipment
|
$
|
399,448
|
$
|
290,864
|
|||
Office
equipment
|
65,077
|
17,339
|
|||||
Furniture
and fixtures
|
7,736
|
7,736
|
|||||
Leasehold
improvements
|
138,692
|
38,368
|
|||||
610,953
|
354,307
|
||||||
Less
accumulated depreciation and amortization
|
(134,664
|
)
|
(57,126
|
)
|
|||
476,289
|
297,181
|
||||||
Construction
in progress (Note 16)
|
366,034
|
--
|
|||||
$
|
842,323
|
$
|
297,181
|
2005
|
2004
|
||||||
Deferred
financing costs, net of accumulated amortization
of $76,746
|
$
|
548,837
|
$
|
--
|
|||
Deferred
charges
|
204,649
|
84,683
|
|||||
Patents
and trademarks, net of accumulated amortization
of $12,318 and $9,380
|
21,614
|
9,425
|
|||||
Licenses,
net of accumulated amortization of $2,674
and $-0-
|
18,656
|
2,187
|
|||||
$
|
793,756
|
$
|
96,295
|
Note
payable to Tri-City Industrial Development Council (TRIDEC),
non-interest
bearing, due in annual installments of $10,000,
maturing
August 2006
|
$
|
20,000
|
||
Note
payable to Benton-Franklin Economic Development District
(BFEDD),
due in monthly installments of $2,855, including interest
and
servicing fee at a combined 8.0%, maturing October 2009
|
222,693
|
|||
Note
payable to Columbia River Bank, due in monthly installments
of
$1,551, including interest at 7.0%, maturing January 2008
|
43,654
|
|||
Convertible
notes payable to investors, interest at 10.0%
payable
quarterly, principal due at maturity in 2006 and 2007
|
318,993
|
|||
605,340
|
||||
Less
amounts due within one year
|
(43,116
|
)
|
||
$
|
562,224
|
|||
Principal
maturities on notes payable are due as follows:
|
||||
2006
|
$
|
43,116
|
||
2007
|
329,685
|
|||
2008
|
65,338
|
|||
2009
|
21,661
|
|||
2010
|
145,540
|
|||
$
|
605,340
|
Year
ending June 30,
|
||||
2006
|
$
|
13,524
|
||
2007
|
13,238
|
|||
2008
|
9,819
|
|||
Total
future minimum lease payments
|
36,581
|
|||
Less
amount due within one year
|
(7,393
|
)
|
||
Present
value of net minimum lease payments
|
29,188
|
|||
Less
amount due within one year
|
(9,604
|
)
|
||
Amount
due after one year
|
$
|
19,584
|
Number
of
Shares
|
Exercise
Price
|
Expiration
Date
|
|||||
7,385
|
$
|
.59
|
July
1, 2005
|
||||
67,520
|
$
|
.59
|
October
30, 2006
|
||||
33,760
|
$
|
.59
|
January
31, 2007
|
||||
7,385
|
$
|
.59
|
February
28, 2007
|
||||
67,520
|
$
|
.59
|
March
30, 2007
|
||||
90,096
|
$
|
.89
|
July
1, 2005
|
||||
90,096
|
$
|
.89
|
February
28, 2007
|
||||
10,339
|
$
|
1.18
|
July
1, 2005
|
||||
10,339
|
$
|
1.18
|
February
28, 2007
|
||||
384,440
|
$
|
.59
to $1.18
|
Number
of
Shares
|
Exercise
Price
|
|
|
Expiration
Date
|
|||
7,385
|
$
|
.59
|
July
1, 2005
|
||||
90,096
|
$
|
.89
|
July
1, 2005
|
||||
10,339
|
$
|
1.18
|
July
1, 2005
|
||||
107,820
|
$
|
.59
to $1.18
|
Number
of
Shares
|
Exercise
Price
|
Expiration
Date
|
|||||
67,520
|
$
|
.59
|
October
30, 2006
|
||||
33,760
|
$
|
.59
|
January
31, 2007
|
||||
7,385
|
$
|
.59
|
February
28, 2007
|
||||
67,520
|
$
|
.59
|
March
30, 2007
|
||||
90,096
|
$
|
.89
|
February
28, 2007
|
||||
10,339
|
$
|
1.18
|
February
28, 2007
|
||||
276,620
|
$
|
.59
to $1.18
|
Net
loss as reported for the year ended June 30, 2005$
|
$
|
4,375,904
|
||
SFAS
No. 123 stock option expense
|
771,365
|
|||
Pro
forma net loss for the year ended June 30, 2005
|
$
|
5,147,269
|
||
Risk-free
interest rate
|
3.50
|
%
|
||
Expected
dividend yield
|
0.00
|
%
|
||
Year
ending June
30,
|
||||
2006
|
$
|
5,400
|
||
2007
|
5,400
|
|||
2008
|
5,400
|
|||
2009
|
5,400
|
|||
2010
|
2,700
|
Item 24.
|
Indemnification
of Directors and Officers
|
Item 25.
|
Other
Expenses of Issuance and Distribution
|
Securities
and Exchange Commission registration fee
|
$
|
4,423
|
||
Transfer
agent fees
|
$
|
2,000
|
||
Accounting
fees and expenses
|
$
|
5,000
|
||
Legal
fees and expenses
|
$
|
75,000
|
||
Blue
sky fees and expenses
|
$
|
10,000
|
||
|
||||
Total
|
$
|
96,423
|
Item 26.
|
Recent
Sales of Unregistered Securities
|
·
|
In
February 2006, the Registrant sold 268,899 shares of common stock,
and
issued an equal number of warrants to purchase common stock, for
cash
proceeds of $1,210,000. These sales were effected pursuant to the
exemption from registration provided by Regulation D promulgated
under the
Securities Act of 1933, as amended (the “Securities Act”), and Section
4(2) of the Securities Act. In connection with this sale, 17,389
warrants
were issued as compensation to certain NASD registered broker-dealers.
|
·
|
Between
October 17, 2005 and January 31, 2006, the Registrant sold 1,500,000
shares of common stock, and issued an equal number of warrants
to purchase
common stock, for cash proceeds of $6,000,000 (less commissions
of ten
percent (10%) on securities placed by broker/dealers). This common
stock
was sold as part of a unit offering including one share of common
stock
and a callable warrant to purchase one share of common stock at
$6.00 per
share with a two-year term. These sales were effected pursuant
to the
exemption from registration provided by Regulation D promulgated
under the
Securities Act, and Section 4(2) of the Securities Act. In connection
with
this sale, 92,159 warrants were issued as compensation to certain
NASD
registered broker-dealers.
|
·
|
On
December 7, 2005, the Registrant entered into a SICAV ONE Securities
Purchase Agreement and a SICAV TWO Securities Purchase Agreement
(collectively, the “Purchase Agreements”) with Mercatus & Partners,
Limited, a United Kingdom private limited Registrant (“Mercatus”).
Pursuant to the Purchase Agreements, Mercatus has agreed, subject
to
receipt of sufficient funding, to purchase 1,778,146 shares of
the
Registrant’s common stock at a purchase price of $3.502 per share. As of
April 21, 2006, no funding had been received by the Registrant
and the
Company intends to request the return of the shares shortly. Pursuant
to
the Purchase Agreements, Mercatus, a foreign entity, was issued
1,778,146
shares of the Registrant’s common stock in exchange for a future cash
payment of $6,227,067.29. If the future payment is not made then
the
shares will be returned. This sale was effected pursuant to Section
4(2)
of the Securities Act.
|
·
|
On
November 18, 2005, the Registrant issued 10,000 shares of common
stock to
Intellegration LLC in
exchange for $40,000 of capital production equipment, consulting
services,
and repair and maintenance services on production equipment used
in the
PIRL facilities pursuant to the exemption from registration provided
by
Section 4(2) of the Securities Act.
|
·
|
On
October 6, 2005, the Registrant issued 24,007 shares of common
stock to
Nuvotec USA, Inc. as payment for one year’s lease of the PIRL facilities
pursuant to the exemption from registration provided by Section
4(2) of
the Securities Act.
|
·
|
In
April 2005, the Registrant sold an aggregate of 2,500,000 shares
(prior to
the Registrant's April 29, 2005 30:1 reverse stock split) for cash
proceeds of $85,000. These shares were sold to three purchasers
- Andrew
Ecclestone (1,470,000 shares), Gary Boster (882,000 shares) and
Philip and
Stephanie Rogers (148,000 shares) - in reliance on the exemption
from
registration provided by Section 4(2) of the Securities Act.
|
·
|
On
December 3, 2003, the Registrant issued 787,100 pre-30:1 reverse
stock
split shares of restricted stock to Thomas Scallen, its former
CEO, as
compensation valued at $7,871, in reliance on the exemption from
registration provided by Section 4(2) of the Securities
Act.
|
·
|
On
December 3, 2003, the Registrant issued 8,675,800 pre-30:1 reverse
stock
split shares of restricted stock to Mark Rosenberg in redemption
of two
notes payable of approximately $36,758, pursuant to the conversion
terms
of the two notes and in reliance on the exemption from registration
provided by Section 4(2) of the Securities Act.
|
·
|
On
June 23, 2003, the Registrant issued an aggregate 53,783,500 pre-30:1
reverse stock split shares of restricted common stock in redemption
of
various outstanding notes payable in the face amount of approximately
$300,000 and accrued interest payable of approximately $237,835,
pursuant
to the conversion terms of the respective notes and in reliance
on the
exemption from registration provided by Section 4(2) of the Securities
Act.
|
·
|
Between
January 31, 2005 and July 10, 2005, IsoRay Medical, Inc. sold
approximately $4,000,000 in principal amount of 8% convertible
debentures
(less commissions of ten percent (10%) on securities placed by
broker/dealers), in reliance on the exemption from registration
provided
by Rule 506 of Regulation D of the Securities Act, that subsequent
to the
merger between the Registrant and IsoRay Medical, Inc. were convertible
into 995,882 shares of common stock of the Registrant. On December
13,
2005, the Board of Directors of the Registrant announced a short-term
conversion inducement to current holders of these convertible
debentures.
Holders were permitted two conversion options: 1) convert under
the
original terms of the debenture to the Company’s common stock at a $4.15
conversion price, and include the newly issued shares in this
registration
statement, or 2) convert under terms essentially identical to
those
offered to purchasers of Units in the Registrant’s offering of October 17,
2005: a $4.00 conversion price and one callable warrant to purchase
one
share of the Company's common stock at an exercise price of $6.00
per
share for each share issued upon conversion (waiving registration
rights
for approximately one year). As of February 10, 2006, holders
of
$3,682,875 of debentures had converted to common stock of the
Registrant.
As of that date, the Registrant had issued 911,276 shares of
common stock,
and 659,469 warrants to purchase shares of common stock, exercisable
at
$6.00 per share, leaving $455,000 in principal amount of debentures
unconverted. Of the 911,276 shares of common stock issued pursuant
to
conversion of the debentures, 251,807 shares are included in
this
registration.
|
·
|
On
March 31, 2005, IsoRay Medical, Inc. issued, in reliance on the
exemption
from registration provided by Section 4(2) of the Securities
Act, 30,303
shares of its common stock and paid $40,000 of cash to Intellegration
LLC
in full satisfaction of the $90,000 purchase price of three laser
welding
stations. Pursuant to the merger with the Registrant, these 30,303
shares
were converted into 25,526 shares of the Registrant’s common stock, of
which all 25,526 are included in this registration.
|
·
|
In
January, 2005, IsoRay Medical, Inc. issued, in reliance on the
exemption
from registration provided by Section 4(2) of the Securities
Act, 211,140
shares of its common stock under §83(b) (subject to a substantial risk of
forfeiture) to certain shareholders as an inducement for their
guarantee
of the Columbia River Bank line of credit and the note payable
to
Benton-Franklin Economic Development District. The transactions
were
recorded at the fair value of the shares, estimated to be $348,381.
Pursuant to the merger with the Registrant, these 211,140 shares
were
converted into 177,856 shares of the Registrant’s common stock, of which
none are included in this registration.
|
·
|
Between
October 15, 2004 and January 21, 2005, IsoRay Medical, Inc. sold
765,500
shares of common stock and issued 229,650 warrants to purchase
shares of
common stock for $.50 per share, for a total of $1,531,000 to
accredited
individual investors, (less commissions of ten percent (10%)
on securities
placed by broker/dealers), in reliance on Rule 506 of Regulation
D of the
Securities Act. All 229,650 warrants were subsequently exercised
prior to
the completion of the merger on July 28, 2005. Pursuant to the
merger, all
995,150 shares of IsoRay Medical, Inc. were converted into 838,277
shares
of the Registrant. Of these shares, 20%, or approximately 167,655
shares,
are included in this registration.
|
·
|
In
connection with the October 15, 2004 private placement, IsoRay
Medical,
Inc. granted, in reliance on the exemption from registration
provided by
Section 4(2) of the Securities Act, the selling broker-dealers
warrants to
purchase 4.23 units at $20,000 per unit. These units represented
42,300
shares of IsoRay Medical, Inc. common stock to purchase 12,690
common
shares at $.50 per share. These units were converted into 35,631
shares of
the Registrant’s common stock and warrants to purchase 10,689 shares of
the Registrant’s common stock at $.59 per share. All 35,631 shares of
common stock are included in this registration.
|
·
|
In
June 2004, IsoRay Medical, Inc. issued 10,000 of its common shares
to Mr.
Girard primarily for services rendered and for $100 cash pursuant
to
Section 4(2) of the Securities Act. The Company recorded $9,900
of
compensation expense in connection with the issuance of these
shares.
During the merger with the Registrant, these 10,000 shares were
converted
into 8,423 shares of the Registrant’s common stock, of which 1,684 are
included in this
registration.
|
·
|
Between
October 15, 2003, and September 30, 2004, in reliance on the
exemption
from registration provided by Section 4(2) of the Securities
Act and Rule
506 of Regulation D of the Securities Act, in a three-phase private
equity
offering prior to the October 1, 2004 business combination of
IsoRay,
Inc., IsoRay Products LLC, and IsoRay Medical, Inc., IsoRay Products
LLC
sold 879,014 Class A shares, 241,500 Class C shares, and issued
127,750
warrants to debt unit investors, to purchase Class A or Class
C shares at
exercise prices ranging from $1.00 to $2.00 for a total of $1,541,417,
less offering costs.
|
Class
A Shares.
The Class A shareholders were entitled to a 15% annual, cumulative
dividend payable quarterly. In connection with the business combination,
the 879,014 IsoRay Products LLC Class A shares were converted
into
1,483,723 IsoRay Medical, Inc. Series B preferred shares. Subsequent
to
the merger with the Registrant, these 1,483,723 IsoRay Medical,
Inc.
Series B preferred shares were converted into approximately 1,249,831
shares of the Registrant’s Series B preferred stock. Subsequent to the
merger with the Registrant, most Series B preferred shareholders
converted
their preferred stock into common stock, and as of February 10,
2006, of
the initial 1,249,831 shares of the Registrant’s Series B preferred stock
issued, only 223,903 shares of Series B preferred stock remain
issued and
outstanding; the balance of 1,025,928 having been exchanged for
shares of
the Registrant’s common stock. Approximately 43,219 shares of common stock
to be received upon conversion of the preferred stock are included
in this
registration.
|
|
Class
B and Class C Shares.
The IsoRay Products LLC Class B and Class C shareholders were
not entitled
to a dividend as were the IsoRay Products LLC Class A shareholders.
In
connection with the business combination, the 2,996,305 IsoRay
Products
LLC Class B, and 241,500 IsoRay Products LLC Class C shares were
converted
into 6,167,426 replacement IsoRay Medical, Inc. common shares.
Subsequent
to the merger with the Registrant, these 6,167,426 IsoRay Medical,
Inc.
common shares were converted into approximately 5,195,205 shares
of the
Registrant’s common stock. Approximately 1,039,041 of these shares are
included in this registration.
|
·
|
Each
debt unit consisted of a $5,000 secured note payable and two warrants.
The
notes payable were secured by the Company's patents, patents pending
and
current patent applications, accrued interest at 10%, payable quarterly,
and matured three years from their issue date. Each warrant entitled
the
holder to purchase 875 IsoRay Products LLC Class A shares. One
of the
warrants was exercisable through July 1, 2005, and the second warrant
is
exercisable through February 28, 2007. The warrant exercise prices
ranged
from $1.00 to $2.00 per share, depending on the IsoRay Products
LLC Class
A share price at the time of the debt unit sale.
|
·
|
In
connection with the business combination between IsoRay Medical,
Inc.,
IsoRay, Inc. and IsoRay Products LLC, the note holders were issued
IsoRay
Medical, Inc. notes payable with substantially the same terms and
conditions as their IsoRay Products LLC notes, and the IsoRay Products
LLC
warrants were exchanged for warrants to purchase 215,640 IsoRay
Medical,
Inc. Series B Preferred shares. Subsequent to the merger with the
Registrant, these warrants to purchase 215,640 IsoRay Medical,
Inc. Series
B Preferred shares were exchanged for approximately 181,647 warrants
to
purchase Series B Preferred shares of the Registrant. As of March
5, 2006,
only 34,836 of the 181,647 warrants remained unexercised, of which
6,967
underlying shares are included in this registration. The entire
$365,000
outstanding secured notes payable, received in the IsoRay Products
LLC
private placement, have now been repaid.
|
·
|
In
connection with the private placement of October 15, 2003, IsoRay
Products
LLC granted warrants for the purchase of 100,000 of its Class A
member
shares to Pinnacle International Holdings, LLC, a financial services
company, pursuant to Section 4(2) of the Securities Act. These
warrants
were exercisable at $1.00 per share. Subsequent to the business
combination of the IsoRay companies, these warrants were exchanged
for
168,799 warrants to purchase IsoRay Medical, Inc. shares of Series
B
Preferred stock at $.59 per share. Pursuant to the merger with
the
registrant, these 168,799 warrants were exchanged for warrants
to purchase
142,190 shares of the Registrant’s common stock at $.70 per share. Of
these 142,190 warrants, 24,438 of the underlying shares of common
stock
are included in this registration.
|
·
|
In
September 2003, Roger Girard, President of IsoRay, Inc., was issued
100,000 IsoRay Products LLC Class B shares primarily for services
rendered
and in reliance on the exemption from registration provided by
Section
4(2) of the Securities Act. IsoRay Products LLC recorded $50,000
of
compensation expense in connection with the issuance of these shares.
Subsequent to the business combination among IsoRay companies,
these
shares were exchanged for 168,798 shares of IsoRay Medical, Inc.,
which
were subsequently exchanged in connection with the merger with
the
Registrant for 142,189 shares of the Registrant’s common stock, of which
28,437 are included in this registration statement.
|
·
|
During
March 2004, IsoRay, Inc. issued 80,000 shares of its common stock
in full
satisfaction of the $80,000 purchase price of a prototype laser
welding
station and in reliance on the exemption from registration provided
by
Section 4(2) of the Securities Act. Subsequent to the business
combination
among IsoRay companies, these 80,000 shares were exchanged for
154,431
shares of IsoRay Medical, Inc. common stock, which were subsequently
exchanged for 130,087 shares of common stock of the Registrant
pursuant to
the Merger. Of those 130,087 shares of common stock, 26,017 are
included
in this registration.
|
·
|
As
of December 2003 IsoRay, Inc. sold 80,000 shares of its common
stock for
$80,000 cash and
in reliance on the exemption from registration provided by Section
4(2) of
the Securities Act. These
80,000 shares of IsoRay, Inc. common stock were exchanged for 154,431
shares of common stock of IsoRay Medical, Inc. This shareholder
sold
92,800 shares of common stock of IsoRay Medical, Inc. at the time
of the
merger. The remaining 61,631 shares of IsoRay Medical, Inc. common
stock
held by this investor were exchanged for 51,915 shares of common
stock of
the Registrant at the time of the Merger, of which 10,382 are included
in
this registration.
|
·
|
As
of December 2002, the Company issued 35,200 shares of its common
stock
pursuant to §83(b) (subject to substantial risk of forfeiture) to certain
shareholders as compensation for their guarantee of notes payable to
Benton-Franklin Economic Development District and in reliance on
the
exemption from registration provided by Section 4(2) of the Securities
Act. The transaction was recorded at the fair value of the shares,
estimated to be $35,200, as management considered it to be more
readily
determinable than the value of the guarantees. During the business
combination among IsoRay companies, these 35,200 shares of common
stock
were exchanged for 67,950 shares of IsoRay Medical, Inc. common
stock,
which were subsequently exchanged the merger with the Registrant,
for
57,238 shares of common stock of the Registrant, none of which
are
included in this
registration.
|
Item 27.
|
Exhibits.
|
Exhibit #
|
|
Description
|
2.1
|
Merger
Agreement dated as of May 27, 2005, by and among Century Park Pictures
Corporation, Century Park Transitory Subsidiary, Inc., certain
shareholders and IsoRay Medical, Inc. incorporated by reference to
the
Form 8-K filed on August 3, 2005.
|
|
2.2
|
Certificate
of Merger, filed with the Delaware Secretary of State on July 28,
2005
incorporated by reference to the Form 8-K filed on August 3, 2005.
|
|
3.1
|
Articles
of Incorporation and By-Laws are incorporated by reference to the
Exhibits
to the Registrant's Registration Statement of September 15,
1983.
|
3.2
|
Certificate
of Designation of Rights, Preferences and Privileges of Series
A and B
Convertible Preferred Stock, filed with the Minnesota Secretary
of State
on June 29, 2005 incorporated by reference to the Form 8-K filed
on August
3, 2005.
|
|
3.3
|
Restated
and Amended Articles of Incorporation incorporated by reference
to the
Form 10-KSB filed on October 11, 2005.
|
|
4.2
|
Form
of Lock-Up Agreement for Certain IsoRay Medical, Inc. Shareholders
incorporated by reference to the Form 8-K filed on August 3,
2005.
|
|
4.3
|
Form
of Lock-Up Agreement for Anthony Silverman incorporated by reference
to
the Form 8-K filed on August 3, 2005.
|
|
4.4
|
Form
of Registration Rights Agreement among IsoRay Medical, Inc., Century
Park
Pictures Corporation and the other signatories thereto incorporated
by
reference to the Form 8-K filed on August 3, 2005.
|
|
4.5
|
Form
of Escrow Agreement among Century Park Pictures Corporation, IsoRay
Medical, Inc. and Anthony Silverman incorporated by reference to
the Form
8-K filed on August 3, 2005.
|
|
4.6
|
Form
of Escrow Agreement among Century Park Pictures Corporation, IsoRay
Medical, Inc. and Thomas Scallen incorporated by reference to the
Form 8-K
filed on August 3, 2005.
|
|
4.7
|
Amended
and Restated 2005 Stock Option Plan incorporated by reference to
the Form
S-8 filed on August 19, 2005.
|
|
4.8
|
Amended
and Restated 2005 Employee Stock Option Plan incorporated by reference
to
the Form S-8 filed on August 19, 2005.
|
|
4.9
|
Form
of Registration Right Agreement among IsoRay Medical, Inc., Meyers
Associates, L.P. and the other signatories thereto, dated October
15,
2004, incorporated by reference to the Form SB-2 filed on November
10,
2005.
|
|
4.10
|
Form
of Registration Rights Agreement among IsoRay, Inc., Meyers Associates,
L.P. and the other signatories thereto, dated February 1, 2006,
incorporated by reference to the Form SB-2/A1 filed on March 24,
2006.
|
|
4.11
|
Form
of IsoRay, Inc. Common Stock Purchase Warrant, incorporated by
reference
to the Form SB-2/A1 filed on March 24, 2006.
|
|
5.1
|
Opinion
of Keller Rohrback, P.L.C., filed herewith.
|
|
10.2
|
Universal
License Agreement, dated November 26, 1997 between Donald C. Lawrence
and
William J. Stokes of Pacific Management Associates Corporation,
incorporated by reference to the Form SB-2 filed on November 10,
2005.
|
|
10.3
|
Royalty
Agreement of Invention and Patent Application, dated July 12, 1999
between
Lane A. Bray and IsoRay LLC, incorporated by reference to the Form
SB-2
filed on November 10, 2005.
|
|
10.4
|
Tri-City
Industrial Development Council Promissory Note, dated July 22,
2002, filed
herewith.
|
|
10.5
|
Section
510(k) Clearance from the Food and Drug Administration to market
Lawrence
CSERION Model CS-1, dated March 28, 2003, incorporated by reference
to the
Form SB-2 filed on November 10, 2005.
|
|
10.6
|
Battelle
Project No. 45836 dated June 20, 2003, filed herewith.
|
|
10.7
|
Applied
Process Engineering Laboratory Apel Tenant Lease Agreement, dated
April
23, 2001 between Energy Northwest and IsoRay, LLC, filed
herewith.
|
|
10.8
|
Work
for Others Agreement No. 45658, R2, dated April 27, 2004 between
Battelle
Memorial Institute, Pacific Northwest Division and IsoRay Products
LLC,
filed herewith.
|
|
10.9
|
Development
Loan Agreement for $230,000, dated September 15, 2004 between
Benton-Franklin Economic Development District and IsoRay Medical,
Inc.,
filed herewith.
|
|
10.10
|
Registry
of Radioactive Sealed Sources and Devices Safety Evaluation of
Sealed
Source, dated September 17, 2004, filed herewith.
|
|
10.11
|
CRADA
PNNL/245, "Y-90 Process Testing for IsoRay", dated December 22,
2004
between Pacific Northwest National Laboratory and IsoRay Medical
Inc.,
including Amendment No. 1, filed herewith.
|
|
10.12
|
Intentionally
Omitted
|
|
10.13
|
Amendment
1 to Agreement 45658, dated February 23, 2005 between Battelle
Memorial
Institute Pacific Northwest Division and IsoRay Medical, Inc.,
filed
herewith.
|
|
10.14
|
Equipment
Lease Agreement dated April 14, 2005 between IsoRay Medical, Inc.
and
Nationwide Funding, LLC, filed herewith.
|
|
10.15
|
Lease
Agreement, Rev. 2, dated November 1, 2005 between Pacific EcoSolutions,
Inc. and IsoRay Medical, Inc., filed herewith.
|
|
10.16
|
Master
Lease Agreement Number 5209, dated May 7, 2005 between VenCore
Solutions
LLC and IsoRay Medical, Inc., filed herewith.
|
|
10.17
|
Contract
#840/08624332/04031 dated August 25, 2005 between IsoRay, Inc.
and the
Federal State Unitary Enterprise << Institute of Nuclear Materials
>>, Russia, incorporated by reference to the Form SB-2 filed on
November 10, 2005.
|
|
10.18
|
State
of Washington Radioactive Materials License dated October 6, 2005,
incorporated by reference to the Form SB-2 filed on November 10,
2005.
|
|
10.19
|
Express
Pricing Agreement Number 219889, dated October 5, 2005 between
FedEx and
IsoRay Medical, Inc., incorporated by reference to the Form 10-QSB
filed
on November 21, 2005.
|
|
10.20
|
Girard
Employment Agreement, dated October 6, 2005 between Roger E. Girard
and
IsoRay, Inc., incorporated by reference to the Form 10-QSB filed
on
November 21, 2005.
|
|
10.21
|
Contract
Modification Quality Class G, dated October 25, 2005 to Contract
Number
X40224 between Energy Northwest and IsoRay, Inc., incorporated
by
reference to the Form 10-QSB filed on November 21,
2005.
|
|
10.22
|
Agreement
dated August 9, 2005 between the Curators of the University of
Missouri
and IsoRay Medical, Inc., filed
herewith.
|
10.23
|
SICAV
ONE Securities Purchase Agreement, dated December 7, 2005, by and
between
IsoRay, Inc. and Mercatus & Partners, Ltd., incorporated by reference
to the Form 8-K filed on December 12, 2005.
|
|
10.24
|
SICAV
TWO Securities Purchase Agreement, dated December 7, 2005, by and
between
IsoRay, Inc. and Mercatus & Partners, Ltd., incorporated by reference
to the Form 8-K filed on December 12, 2005.
|
|
10.25
|
Economic
Development Agreement, dated December 14, 2005, by and between
IsoRay,
Inc. and the Pocatello Development Authority, incorporated by reference
to
the Form 8-K filed on December 20, 2005.
|
|
10.26
|
License
Agreement, dated February 2, 2006, by and between IsoRay Medical,
Inc. and
IBt SA, incorporated by reference to the Form 8-K filed on March
24, 2006
(confidential treatment requested).
|
|
10.27
|
Benton
Franklin Economic Development District Loan Covenant Waiver Letter,
dated
as of March 31, 2005, filed herewith.
|
|
10.28
|
Service
Agreement between IsoRay, Inc. and Advanced Care Medical, Inc.,
dated
March 1, 2006, filed herewith.
|
|
16.1
|
Letter
from S.W. Hatfield, CPA to the SEC dated December 13, 2005, incorporated
by reference to the Form 8-K filed on December 14,
2005.
|
|
21.1
|
Subsidiaries
of the Registrant, incorporated by reference to the Form 10-KSB
filed on
October 11, 2005.
|
|
23.1
|
Consent
of Keller Rohrback, P.L.C. (included in Exhibit 5.1)
|
|
23.2
|
Consent
of S.W. Hatfield, CPA, filed herewith.
|
|
23.3.
|
Consent
of DeCoria, Maichel & Teague, P.S., filed
herewith.
|
Item 28.
|
Undertakings.
|
By: | /s/ Roger E. Girard |
Roger
E. Girard, Chairman and Chief Executive
Officer
|
Signature
|
Title
|
Date
|
||
/s/
Roger E. Girard
Roger
E. Girard
|
Chief
Executive Officer and Chairman
|
April
26, 2006
|
||
/s/
Michael K. Dunlop
Michael
K. Dunlop
|
Chief
Financial Officer and Principal Accounting Officer
|
April
26, 2006
|
||
/s/
Dwight Babcock
Dwight
Babcock
|
Director
|
April
26, 2006
|
||
/s/
Stephen R. Boatwright
Stephen
R. Boatwright
|
Director
|
April
26, 2006
|
||
/s/
Robert R. Kauffman
Robert
R. Kauffman
|
Director
|
April
26, 2006
|
||
/s/
Thomas C. Lavoy
Thomas
C. Lavoy
|
Director
|
April
26, 2006
|
||
/s/
Albert Smith
Albert
Smith
|
Director
|
April
26, 2006
|
||
/s/
David J. Swanberg
David
J. Swanberg
|
Director
|
April
26, 2006
|